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ABSTRACT 
Generation of the sodium/myo-inositol cotransporter 1 (Slc5a3) gene murine knockout 
model, characterization of its lethal phenotype, and revision of the ‘inositol depletion 
hypothesis’. 
Roberto Buccafusca 
Gerard T. Berry, M.D. and Donald L. McEachron, Ph.D. 
 
 
Myo-inositol (Ins) is a ubiquitous hexahydroxycyclohexane in living organisms, 
and the most abundant in mammalian cells of all nine possible stereoisomers along with 
scyllo-, neo-, epi-, muco-, allo-, cis-, and the enantiomers, D-chiro and L-chiro.  Ins is an 
important osmolyte and a key component of phosphatidylinositol (PtdIns), unique in the 
family of phospholipids in that its Ins headgroup can be further phosphorylated to 
generate various phosphoinositides. Among them, phosphatidylinositol-4,5-bisphosphate 
(PtdIns-4,5-P2) is involved in important signal transduction events.  Ins’s cellular uptake 
is carried out by a system of specific membrane transporters, of which the SLC5A3 
(SMIT1), a Na+/myo-inositol cotransporter, is the one with the highest affinity for the 
polyol.   
The principle aim of my thesis work is to test the widely accepted “myo-inositol 
depletion hypothesis” envisioned to explain the mechanism of action of lithium, 
complications of diabetes and hereditary galactosemia.  This assumption, which states 
that a reduction of intracellular myo-inositol results in a decreased PtdIns synthesis, and 
therefore a disruption of cellular signaling, had never been tested by direct measurements 
of PtdIns.  To investigate the effect of Ins deficiency at the cellular level, a murine 
knockout model of the Slc5a3 gene encoding the Na+/Ins cotransporter was generated and 
studied.  The resulting Slc5a3-null mice die shortly after birth, although the phenotype 
xvii 
 
can be rescued by supplementation of 1% Ins in the drinking water of the pregnant dam.  
The rescued Slc5a3 knockout mice survive only if the Ins enriched water treatment 
continues until weaning, 14 days after birth. 
 My work shows that a 69.7% reduction in myo-inositol is responsible for a 47% 
reduction of PtdIns in the murine Slc5a3–null fetus at embryonic stage 10.5, but the 
hypothesis proves to be invalid at later stages of development, at embryonic stages 14.5 
and at 18.5, and through adulthood.   The work outlined in this dissertation also shows 
that the ‘Ins depletion hypothesis’, as it has been proposed, proves to be invalid since Ins 
levels in mammalian tissues have never been shown to be reduces to the degree observed 
in Slc5a3 knockout mouse model used in my study. 
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CHAPTER 1     BACKGROUND AND LITERATURE SURVEY 
 
Myo-inositol (Ins) is a 1,2,3,4,5,6-hexahydroxy-cyclohexane, a six-carbon 
polyol, ubiquitous in nature, and the most abundant occurring isomer of all 
possible nine inositol isomers along with scyllo-, neo-, epi-, muco-, allo-, cis-, and 
the enantiomers D-chiro, and L-chiro.  Scyllo-inositol is the second most 
abundant of the nine isomers, and  it accounts for 5 to 10% of that of myo-inositol 
in mammalian brain[1].   
 
 
 
 
 
 
 
 
 
Figure 1. The molecular structures of the inositol isomers. Chiro-inositol 
occurs as both D- and L-enantiomers, but only one of them is pictured.  Myo-
inositol has an axial -OH group attached to the 2-carbon, and the remaining 
hydroxyls are equatorial.  The carbons are numbered in an anticlockwise 
direction. 
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Myo-inositol is a major compatible osmolyte in mammalian cells, and like 
other organic non-perturbing solutes such as betaine, taurine, 
glycerophosphorylcholine and sorbitol, accumulates in cells to the effect of 
restoring osmotic homeostasis, and thereby cell volume,  under drastic changes in 
extracellular tonicity [2, 3].  The cyclic polyol is also the component of 
phosphatidylinositol (PtdIns),  a membrane-bound phospholipid in which the 
myo-inositol ring can be reversibly phosphorylated at position(s) 3, 4 and 5, 
generating an array of phosphatidylinositolpolyphosphates or phosphoinositides, 
the most abundant being phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P2).  
Following cell-surface receptor–mediated activation of phospholipase C,  PtdIns-
4,5-P2 is hydrolyzed generating two important signal transduction molecules:  
inositol-1,4,5-trisphosphate (Ins-1,4,5-P3) which regulates the release of 
intracellular calcium stored in the endoplasmic reticulum, and diacylglycerol 
(DAG), an activator of protein kinase C [4].   This canonical signaling pathway in 
multicellular organisms in which myo-inositol plays a major role is cyclical in 
nature as the polyol is continuously required to be incorporated into PtdIns.   
Inositol-1,4,5-trisphosphate (Ins-1,4,5-P3) has been the most well studied 
inositolpolyphosphate, and following its discovery, a vast array of 
inositolpolyphosphates were unveiled having biological functions such as in ion-
channel physiology, in membrane dynamics and in nuclear signaling.  Figure 2 
summarizes the physiological and biochemical importance of myo-inositol in the 
synthesis of phosphoinositides and inositolpolyphosphates.   
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Figure 2.   The two most elucidated roles of myo-inositol in mammalian 
physiology.  The figure depicts the biochemical pathways of myo-inositol in the 
synthesis of PtdIns, phosphoinositides, inositolpolyphosphates, and its catabolism 
in the kidneys in which myo-inositol is metabolized into glucuronic acid first by 
action of the myo-inositol oxygenase in a cascade that yields fructose-6-P and 
glucose-6-P via the pentose phosphate pathway[5].   
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Theoretically the intracellular myo-inositol pool is derived from three 
different sources: the diet, de novo synthesis from glucose utilizing myo-inositol-
1-phosphate syntethase (MIP) and myo-inositol monophosphatase 1 (IMPase1), 
and from the breakdown and recycling of phosphoinositides [6-9].  Uptake of 
dietary myo-inositol in mammalian cells via active transport against a 
concentration gradient 5-100 fold higher than in the extracellular fluid[6, 10]  is 
through action of a transmembrane protein, the sodium-dependent myo-inositol 
cotransporter SLC5A3, the third member of the carrier family 5, also designated 
as the protein,  SMIT1[11, 12].   
1.1  Role of myo-inositol in cellular adaption to osmotic stress 
Myo-inositol plays a major role in cellular adaptation to osmotic stress, a 
biological mechanism that protects organisms from deleterious effects of cell 
shrinkage due to water loss, or swelling of cells due to accumulation of water, to 
counteract a hypotonic extracellular environment[2, 13, 14].  To avoid the adverse 
effect of cell volume perturbations and disruption of inorganic ions homeostasis, 
cells avail themselves of uncharged osmolytes such as betaine, taurine, sorbitol 
and myo-inositol [2, 15].   Studies done in vivo show marked decrease of myo-
inositol in brains of hyponatremic mice, and a contrasting increase of the polyol in 
hypernatremic Swiss Webster mice[3].  Concurringly, in vitro studies using 
Madin-Darby canine kidney (MDCK) cells reveal enhanced myo-inositol 
accumulation in response to augmented hypertonicity of the culture media, and in 
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response to increased activity of the SLC5A3 Na+/myo-inositol cotransporter [16, 
17].  
1.2 Structure of the Na+-dependent myo-inositol cotransporter SLC5A3 
 Kwon and colleagues isolated the canine SLC5A3 cDNA from Madin-
Darby canine kidney (MDCK) cultured cells, and following its expression in 
Xenopus oocytes, revealed a 718 aminoacid with 12-14 membrane-spanning 
domains with both the amino and carboxy terminals on the cytoplasmic side of 
the cellular membrane, with several putative phosphorylation sites present only on 
the cytosolic side of the protein[17].  Canine   SLC5A3 gene is highly 
homologous (40-50%) to the Na+/D-glucose cotransporter [18], and to the human 
SLC5A3 gene hortologue[11].  
The human SLC5A3 gene is located on the long arm chromosome 
21q22.1[11].  Other myo-inositol cotransporters, such as the human SMIT2 [19] 
and the human H+- myo-inositol (HMIT) [20] exist, but both have a lower affinity 
for the polyol, and their role in physiology is uncertain.  HMIT is expressed 
prevalently in the CNS, mostly in astrocytes, and it is active at low pH, whereas 
SLC5A3 is inhibited at low pH[21].  Indeed, myo-inositol’s uptake is pH-
dependent, and requires two Na+ ions for each molecule carried across the 
membrane.  Myo-inositol and scyllo-inositol have the highest affinity for the 
transporter with a Km in the order of 12 to 50 µM[22]. 
 
 
6 
 
1.2.1 SLC5A3 and its cognate gene MRPS6 
The human SLC5A3 gene and the mitochondrial 28S ribosomal protein S6 
gene (MRPS6) share the same telomeric region on the human chromosome 21, 
and equal transcriptional orientation[23, 24]. Data from genomic sequence 
analysis show that both genes share exon1, which is part of the open reading 
frame of the MRSP6 gene, but not of the SLC5A3 gene[25].   
The mitochondrial ribosomal protein subunit 6 (MRPS6) is a small 125AA 
ribosomal  protein encoded by a gene that spans about 69.5 Kb of genomic 
space[23] (figure 3).  The gene consists of three small exons.  Its first exon is 
shared with the exon 1 of the SLC5A3.  MRPS6’s Exon 1 contains part of the 
coding region of the MRPS6 gene, but not of the SLC5A3gene.  The reading 
frame of the sodium/inositol cotransporter is embedded within intron 1 of the 
MRPS6 gene. The SLC5A3 and MRPS6 genes therefore share the same genomic 
space and are both located on the human chromosome 21q22.1 region[26].   
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Figure 3.  Organization of  SLC5A3 and MRPS6 along the same genomic 
space on the human chromosome 21q22.1 region[26].   
 
 
1.3  Tissue expression of the SLC5A3 RNA message 
Expression of the  SLC5A3 RNA message is detected in a few select 
organs; it is highest in brain, kidney and testis, but absent in liver and skeletal 
muscle[26].  During development the myo-inositol carrier is highly expressed in 
fetal brain, as well as in placenta, but its expression declines post-natally[27, 28].  
Expression and regulation of the SLC5A3 gene is thought to be modulated by the 
transcription factor tonicity enhancer binding protein (TonEBP) [29]  which is 
activated under hypertonic conditions and binds to tonicity responsive elements 
(TonE) on the promoter region of the SLC5A3 gene, modulating its 
transcription[29, 30].   Regulation of the SLC5A3 gene is thought to also occur 
post-translationally by action of the glucocorticoid-inducible kinase, SGK1, 
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which would modulate phosphorylation at some putative sites of the 
transmembrane Na+/myo-inositol carrier since a similar mechanism of modulation 
of protein activity has been shown in various ion channels and transporters [31, 
32].   
In clinical settings perturbation of myo-inositol metabolism has been hypothesized 
as a mechanism responsible in the pathogenesis of diabetic neuropathy [33], and 
alterations in brain and cerebrospinal fluid Ins concentrations have been reported 
in various pathological conditions such as in the pre-dementia phase of 
Alzheimer’s disease [34, 35] and in Down syndrome [36]. 
1.4 De novo synthesis of myo-inositol from glucose 
Myo-inositol is synthesized de novo from glucose in blood-brain barrier 
capillary pericytes, testis, kidney, placenta, and in fetal tissues [37-41].  Glucose 
6-phosphate is the substrate of the enzyme D-inositol-3-phosphate synthetase 
(MIP, EC 5.5.1.4) which catalyzes the condensation reaction to yield D-inositol-
3-phosphate.  This mechanism converts glucose into myo-inositol without scission 
of the six carbon chain and it requires nicotinamide adenine dinucleotide (NAD), 
and it is stimulated by NH4+ and K+.  The D-inositol-3-phosphate is then 
hydrolyzed to myo-inositol by the enzyme inositol monophosphatase 1(IMPase 1, 
EC 3.1.3.25) which requires Mg+, and inhibited by Li+.  
1.5 Synthesis of phosphatidylinositol and polyphosphoinositides 
In mammalian cells de novo biosynthesis of phosphatidylinositol takes 
places in the endoplasmic reticulum (ER) directly from myo-inositol by action of 
9 
 
the phosphatidylinositol synthetase (CDP-diacylglycerol:myo-inositol 3-
phosphatidyl-transferase, EC 2.7.8.11)[6], a 24-kDa membrane-bound enzyme, 
which catalyzes the condensation of CDP-diacylglycerol (CDP-DAG) and myo-
inositol to form PtdIns and CMP.  PtdIns-synthetase is ubiquitously distributed 
among mammalian species and tissues, and analysis of its distribution in rat 
tissues showed higher activity of the enzyme in brain and liver and low in skeletal 
muscle [42]. At the subcellular level, the PtdIns synthetase is localized in the 
endoplasmic reticulum [42-44].  Studies done on microsomal preparations show 
that PtdIns-synthetase requires high concentration of Mg2+ in the order of 40-60 
mM for optimal activity[43], and its Km for phosphatidic acid, the 
phosphorylated form of diacelglycerol and the precursor of CDP-DAG,  is 2.5 
mM.  CDP-DAG is present in very low concentrations, and very hard to quantify 
in tissues, which indicates that the activity of the PtdIns-synthetase could be rate-
limiting for PtdIns synthesis.  Nevertheless, studies done using [3H]cytidine-
labeled CDP-DAG have shown that it accumulates in cells in the presence of 
lithium, and this effect can be reversed by increasing concentrations of myo-
inositol[45].  The effect of lithium on the in vitro synthesis of PtdIns gave support 
to the ‘inositol depletion hypothesis’ since lithium effects the turnover of myo-
inositol due to its inhibitory effect on inositol phosphate monophosphatase.  The 
predominantly abundant mammalian phosphatidylinositol has stearate and 
arachinodate as the major saturated (sn-1) and unsaturated (sn-2) fatty acids[46, 
47].   
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Following its synthesis in the ER, PtdIns is delivered to the cell membrane 
either by PITPs (PtdIns transfer proteins), or by budding of the ER membrane and 
fusion to the cell membrane via vesicular transport.  PIPTs mobilize PtdIns from 
the ER to the cell membrane, and thereby their activity and availability modulate 
the discrete pool of PtdIns at the membrane level.  The role of PIPTs has been 
demonstrated in yeast studies[48], and so far three mammalian isoforms of PIPTs 
have been identified, two of them localized in the Golgi complex and implicated 
in the regulation of exocytosis[49].   The myo-inositol ring of the membrane-
bound PtdIns is reversibly phosphorylated at positions 3, 4 and 5 in a 
combinatorial way to generate seven phosphoinositides.  In mammalian cells, 
PtdIns comprises about 10-15 % of the total phospholipid pool and the most 
abundant membrane phosphoinositides, PtdIns-4-P, and PtdIns-4,5-P2 are about 
ten times lower in concentrations.   
Hydrolysis of phosphatadylinositol-4,5-bisphosphate by phospholipase C 
yields two important signal transduction molecules, myo-inositol-1,4,5-
trisphosphate (Ins-1,4,5-P3) which regulates the release of intracellular calcium 
stored in the ER, and diacylglycerol (DAG), an activator of protein kinase 
C(PKC)[4].  Activation of the phosphodiesterase, phospholipase C, mediated by 
agonists binding to cell-surface receptors, known as “PtdIns effect” was an 
accidental observation when pigeon pancreas cells grown in the presence 32Pi 
revealed an increase in “RNA phosphorylation” upon stimulation of the cells with 
acetylcholine.  The detected increase in 32Pi incorporation into “RNA” was later 
found to be that of radiolabeled phospholipids, contaminants of the isolated RNA 
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[8].  The increase was also reversed by cholinergic antagonists such as atropine. 
The same incorporation was observed following exposure of the acetylcholine-
stimulated pancreatic cells to [3H]-myo-inositol, although the degree of 
incorporation was less pronounced than in 32Pi labeled cells[50, 51] in that  
phospatidylethanolamine and phosphatidylcholine were also labeled[52].   
1.6 Functions of polyphosphoinositides 
Myo-inositol lipids are integrated into the cytosolic side of the cell 
membrane where they exert signaling functions by binding their hydrophilic head 
group to cytosolic protein, or cytosolic domains of membrane proteins mostly by 
electrostastic interactions with a phosphate moiety on the myo-inositol ring, 
although it has been shown that the interaction involves partial penetration of 
hydrophobic aminoacid residues of  the interacting proteins into the lipid 
bilayer[53, 54].  Phosphoinositides interaction with membrane-bound proteins 
occurs via basic residues in the protein, or by interaction with the pleckstrin 
homology domain [53-55]. 
PtdIns-4,5-P2 is the most well studied of all the phosphoinositides due to 
its involvement in the signaling pathway that yields water soluble Ins-3,4,5-P3 and 
membrane-associated DAG second messengers upon hydrolytic cleavage by 
phospholipase C.   However, PtdIns-4,5-P2 plays additional pivotal roles.  For 
example, it is an important plasma membrane signal that establishes sites for 
vesicular trafficking, membrane movement, and actin cytoskeletal assembly. The 
docking role of PtdIns-4,5-P2 is mediated through interactions with proteins 
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required for membrane trafficking and cytoskeleton assembly that contain PtdIns-
4,5-P2 -binding domains[6, 56-58]. 
PtdIns-4, 5-P2 is the product of the phosphorylation of PtdIns-4-P, or the 
less known PtdIns-5-P, by type I and II  PtdInsP kinases, respectively.  PtdIns-
4,5-P2 can be further phosphorylated to PtdIns-3,4,5-P3, and although this 
particular lipid is found in minimal amounts in cell membrane, it has been linked 
to many regulatory mechanisms such as cell proliferation, and differentiation[59, 
60], including the akt/protein kinase B mitotic pathway.   
PtdIns-4,5-P2 promotes dissociation of capping proteins such as gelsolin 
and Capz and therefore hindering elongation of actin filaments[61].  It binds 
profilin, and promotes dissociation of the complex bewteen monomers of 
actin[61], and it is also involved in binding of adaptor proteins responsible for 
creating the structure scaffold within the cell by anchoring actin filaments to the 
cell membrane, and in cell-cell adhesion.  In mammalian cells, PtdIns-4,5-P2 is 
thought to be essential for maintaining Golgi organization and protein trafficking 
through the Golgi[62], and it is essential for vesicle membrane fusion in a number 
of systems[63] .   
1.7 The myo-inositol-1,4,5-trisphosphate signaling molecule 
The role of myo-inositol-1,4,5-P3 as a second messenger in what is called 
“Ca2+ gating”, the release of calcium stores from the endoplasmic reticulum (ER), 
was first observed by Berridge et al. [64] following stimulation of blowfly 
salivary glands with 5-hydroxytryptamine (5-HT, a neurotransmitter)  in which he 
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reported an increased production of myo-inositol-1,4,5-P3.  In a later publication 
the author  also observed that when pancreatic cells, or hepatocytes, were exposed 
to myo-inositol-1,4,5-P3 following treatment with membrane permeabilizing 
agents to allow myo-inositol-1,4,5-P3 to enter the cells, Ca2+ was shown to be 
released form ER stores in 45Ca2+ radioisotope-labeled experiments [65].  “Ca2+ 
gating” is not observed with other myo-inositol polyphosphates[65], and myo-
inositol-1,4,5-P3 does not release Ca2+ from mitochondria.  To release Ca2+ from 
the endoplasmic reticulum, myo-inositol-1,4,5-P3 must bind to receptors linked to 
calcium channels that interact with the myo-inositol-1,4,5-P3-sensitive calcium 
pool.  Myo-inositol-1,4,5-P3-sensitive calcium channels have been isolated from 
membrane vesicles of aortic smooth muscle cells[66].  Myo-inositol-1,4,5-P3 
receptors and their regulation of Ca2+ channels have been under intense 
investigation for the past two decades. 
The action of many agonists mobilize calcium through myo-inositol-1,4,5-P3 from 
calcium-sensitive stores, but also trigger influx of external calcium as it has been 
reported in studies done on regulation of calcium entry in lymphocytes[67] and 
mast cells[68].  This includes the physiological phenomenon of calcium-included 
calcium release.  So far, it’s not very clear how myo-inositol-1,4,5-P3 is involved 
in the uptake of calcium from the cellular environment, but  the accepted 
hypothesis is that the control of calcium entry is  indirectly regulated by the 
ability of myo-inositol-1,4,5-P3 to discharge  calcium from the endoplasmic 
reticulum pool since it has been widely reported that emptying of an internal 
calcium stores precedes calcium entry from the cellular milieu.  To exert this 
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function myo-inositol-1,4,5-P3 works in concert with myo-inositol-1,3,4,5-P4 
present in very low concentrations in cells, but also  plays a role in increasing 
intracellular calcium only if  myo-inositol-1,4,5-P3 is present[69, 70].  The 
proposed mechanism by which myo-inositol polyphosphates control calcium entry 
into cells is that myo-inositol-1,4,5-P3 moderates calcium channel in the plasma 
membrane[67, 68], and releases calcium from the endoplasmic reticulum, whereas 
myo-inositol-1,3,4,5-P4 controls the transfer of calcium from intracellular pools 
other than the endoplasmic reticulum as a way to replenish the organelle’s 
calcium storage[71].  
 1.8 Biological importance of the second messenger diacylglycerol 
Diacylglycerol, or 1-steroyl-2-arachidonoyl-sn-glycerol, activates protein 
kinase C which requires Ca2+ to maximize its kinetic activity.  In this sense, both 
diacylglycerol and myo-inositol-1,4,5-P3 work in concert with each other.  Myo-
inositol-1,4,5-P3 triggers release of calcium from the ER which is then utilized as 
a cofactor by protein kinase C to phosphorylate an array of proteins.   
1.9  Synthesis and roles of myo-inositol polyphosphates 
In mammalian cells myo-inositol-1,4,5-P3 can be sequentially 
phosphorylated by inositol polyphosphate multikinase (mIPMK)[72] at positions 
3’ and 6’ to yield myo-inositol-1,3,4,5-P4 and myo-inositol-1,3,4,5,6-P5.  In 
neuronal tissues a highly specific myo-inositol-1,4,5-P3 3-kinase can 
phosphorylate myo-inositol-1,4,5-P3 to myo-inositol-1,3,4,5-P4[73].     
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A 1,3,4,5,6-pentakisphosphate 2-kinase (myo-inositol-P5 2-kinase) capable of 
phosphorylating myo-inositol-1,3,4,5,6-P5 to myo-inositol hexakisphosphate 
(myo-inositol-1,2,3,4,5,6-P6) has been recently isolated in mammalian cells[74].  
Myo-inositol-1,3,4,5,6-P5 2-kinase is  highly expressed  in brain, heart, placenta, 
and testis[74].   
Myo-inositol hexakisphosphate, apart from myo-inositol-1,4,5-P3, has been studied 
extensively and it plays a major role in many physiological functions.  In non-
neural tissues is thought to be anti-neoplastic[75], and to act as a cellular 
antioxidant[76].  In the central nervous system myo-inositol-P6 may also play a 
very important role since protein preparations from different brain regions show 
high affinity for the myo-inositol hexakisphosphate  [77], it also binds with high 
affinity proteins associated with membrane trafficking roles, such as AP-2[78], 
AP180[79], and synaptogamin[80].  
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CHAPTER 2      INTRODUCTION 
 
 
  A major attempt of my thesis work was to test the “inositol deletion 
hypothesis” first proposed by Berridge[81] which postulates that intracellular 
myo-inositol deficiency results in the reduction of levels of phosphatidylinositol 
and polyposphoinositides, its phosphorylated derivatives, since the polyol is a key 
structural component of these phospholipids.  Although the hypothesis has never 
been properly tested by direct measurements of phosphatidylinositol (PtdIns) or 
polyphosphoinositides (PtdInsPn) in the relevant mammalian tissues, its 
contenders base their claim purely on works done on lithium in an effort to 
suggest a metabolic explanation for its therapeutic use in the treatment of bipolar 
disorders.  Lithium may exert an effect on myo-inositol-phosphate signaling;  and 
it is an inhibitor of inositol monophosphatase 1 [82] and polyphosphatase [83], 
two enzymes involved in the breakdown and recycling of myo-inositol-1,4,5-P3.   
The effect of Li+ to reduce intracellular myo-inositol was first reported by Allison 
et al. in 1971 following  measurements of the polyol in the cerebral cortex of rats 
treated with Li+[84].  In the years that followed, decreased myo-inositol levels 
were associated with elevated concentrations of myo-inositol-1-phosphate as a 
direct consequence of inhibition of the myo-inositol 1-phosphatase[85-88].  In a 
1982 publication Berridge et al. conducted a series of studies that implicated myo-
inositol levels and phosphoinositide-cycle regulation in the pathophysiology of 
bipolar disorders.  Berridge postulated the “inositol depletion hypothesis” based 
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on studies done on blowfly (Calliphora erythrocephala) salivary glands[81]. In 
their pioneering work Berridge et al.  bathed the salivary glands in a medium 
containing [2-3H] myo-inositol, and following multiple washes, the tissues were 
incubated with Li+ alone, or Li+  in combination with 5-hydroxytryptamine (HT-2, 
a stimulating hormone).  The group observed an inhibitor effect of Li+ on the 
recycling of intracellular labeled myo-inositol, demonstrating an accumulation of 
[2-3H] myo-inositol-1-phosphate and a corresponding decrease in free labeled 
myo-inositol.  The group concluded that intracellular myo-inositol depletion upon 
chronic exposure to Li+ was directly linked to the impaired phosphatidylinositol 
synthesis and recycling, and not from the de novo synthesis from glucose, proven 
by the accumulation of the D-enantiomer of myo-inositol-1-phosphate which 
comes solely from the breakdown of PtdIns. 
Throughout the years since it was first introduced,  the “inositol depletion 
hypothesis” has been challenged by some, but it has continued to generate 
enthusiasm in the scientific field, and has also been used to explain mechanisms 
of diabetic neuropathy[33], and the onset of neurotoxicity in patients with 
hereditary galactosemia[89].   
Myo-inositol metabolism and function of the Slc5a3 gene is the topic 
outlined in the research I am presenting as a means to assess the “inositol 
depletion hypothesis”.  To investigate potential deleterious effect of intracellular 
myo-inositol deficiency, I took part in the generation of a murine Slc5a3 gene 
knockout model to evaluate consequential biochemical and physiological 
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activities in cells in which the activity of the major mammalian Na+/myo-inositol 
cotransporter is completely obliterated.  Most importantly, the murine knockout 
model allows us to evaluate the long held “inositol depletion hypothesis” by 
directly testing whether intracellular myo-inositol insufficiency leads to a 
dampening of phosphatidylinositol synthesis by direct measurements of these 
membrane phospholipids utilizing the most innovative instrumentation available 
today.    
The Slc5a3 gene was successfully ablated by gene targeting by disrupting 
the 2157 bp coding region in exon 2, and replacing it with the neomycin resistant 
gene minicassette used for the positive selection of the murine Slc5a3-null 
embryonic stem cells [90].  Slc5a3 knockout newborns die right after birth, about 
twenty minutes post-partum, but develop normally with no evident morphological 
phenotype; their weights at birth are comparable to those of their wildtype 
counterparts, and have no gross physiological malformations [90].   Although a 
physiological phenotype has not been proposed for the Slc5a3 knockout model, 
we hypothesize that the Slc5a3 knockout newborns die postpartum due to 
hypoventilation [90].  This is substantiated by electrophysiological studies done in 
collaboration with Dr. John Greer at the University of Alberta, Canada, in which 
diaphragm electromyography recordings from Slc5a3 knockout E18.5 newborns 
show irregular respiratory rhythmic patterns, supporting the hypothesis that myo-
inositol  insufficiency may be detrimental at the moto-neuronal level in which 
transmission of the respiratory path from the preBötzinger complex (preBötC), 
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the brain stem respiratory pacemaker, to the diaphragm via the phrenic nerves is 
impaired.  
The Slc5a3 knockout phenotype is ”rescued” by supplementing the 
drinking water of the pregnant dam with 1% myo-inositol.  This treatment ensures 
survival of Slc5a3-null mice, but it is only effective if administered until weaning, 
14 days post-partum.  Interruption of the 1% myo-inositol treatment results in a 
premature death of the newborn Slc5a3 knockout mice.  
Myo-inositol concentrations were measured in brains and the whole body of 
untreated Slc5a3 knockout newborns at embryological stage 18.5, and in fetuses 
at an earlier stage of development at E10.5, and at E14.5.   Basal levels of myo-
inositol are 96% lower in brains of E18.5 Slc5a3-impaired mutant fetuses than in 
wildtypes, while at the onset of development, at embryonic stage 10.5, myo-
inositol levels in knockout are only reduced by 69.7% in comparison to levels of 
the polyol in wildtype littermates.  Upon treatment with 1% myo-inositol, basal 
levels of myo-inositol are not restored in brains of E18.5 Slc5a3 knockout mice, 
but are normalized in E10.5 Slc5a3 knockout embryos.   
 The murine Slc5a3 knockout model is the first animal model in which 
myo-inositol levels are markedly reduced, and the first ever observed massive 
myo-inositol deficiency state in any living system, either in lower or complex 
organisms.  The model offers a useful tool to study the role on myo-inositol, its 
impact on neuronal plasticity, its role in organ formation and function, and mostly 
importantly, it allows us to delineate a correlative biochemical relationship 
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between myo-inositol deficiency and phosphatidylinositol synthesis.  Although a 
quasi-total depletion of intracellular myo-inositol in brains of Slc5a3-null E18.5 
fetuses fails to demonstrate disruption of membrane phosphatidylinositol, in 
Slc5a3-knockout embryos at fetal stage 10.5 a 69.7% myo-inositol reduction leads 
to a 47% decrease of membrane-bound PtdIns. Therefore, ablation of the major 
murine Na+/myo-inositol cotransporter gene generates a metabolic phenotype that 
allows us to further investigate the mechanism of lethal myo-inositol deficiency, 
and to re-evaluate the “inositol depletion hypothesis”.  
The most compelling  scientific evidence outlined in this thesis 
demonstrates that  myo-inositol deficiency in the brain of Slc5a3 knockouts may 
lead to a dampening of phosphatidylinositol levels in the earliest stage of 
embryogenesis prior to the full neuronal development and axonal arborization, 
and that rescue of the phenotype alleviates the lethal effect of myo-inositol 
deficiency by increasing the myo-inositol pool size above a certain threshold, in 
the 100-300 µM range,  in which phosphatidylinositol synthesis and levels are 
restored to a viable and life-sustaining level. 
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CHAPTER 3     EXPERIMENTAL PROCEDURES AND RESULTS   
3.1 Generation of the Slc5a3 knockout animal model 
The targeting vector used to ablate the genomic Slc5a3 gene by 
homologous recombination was constructed from an initial 129/Sv lambda phage 
mouse library clone containing a 15 Kb fragment encasing the murine Slc5a3 
gene, the ortholog to the human SLC5A3 gene (figure 4).  A detailed restriction 
map was developed from this genomic clone, and an 11Kb Xba I fragment was 
ultimately used to construct a pGK targeting vector.  Gene inactivation was 
accomplished by replacing the 1.6 Kb EcoRI-NcoI fragment within the murine 
Slc5a3 open reading frame (ORF) in the Slc5a3(11Kb)-pSK clone with a 1.9 Kb 
phosphoglycerate kinase (PGK)-neo cassette (neomycin resistance gene), used a 
selectable marker to identify and isolate the stem cells that had successfully 
undergone genetic recombination, hence gene replacement.  A separate minigene, 
the HSV-tk-DTa (a gift from Dr. Nancy Cooke at the University of Pennsylvania, 
Philadelphia, PA) was ligated to the 3´end of the vector to allow negative 
selection of non-targeting events.   
The engineered targeting vector was introduced into 129svJ mouse 
embryonic stem (ES) cells by electroporation, and neomycin resistant clones were 
isolated.  A 1 kb SacI fragment 5´ to the homology contained in the targeting 
vector (probe 1 in figure 4) was used as a probe in Southern blot analyses to 
identify “positive clones” in which homologous recombination occurred.  HindIII 
digestion of the wild type locus generates a 9 kb fragment detectable by probe 1, 
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while the correctly targeted locus yields an 11 kb fragment (figure 5A).  A total of 
12 correctly targeted clones were identified among 192 resistant clones.  Only one 
clone was utilized for blastocyst injection, and implanted into a pseudo pregnant 
C57Bl6 female mice.  Blastocyst injections and uterine implantation were 
performed by the transgenic animal facility at the University of Pennsylvania.   
  Following gestation, 8 chimeric mice were obtained, 4 transmitted ES 
cell DNA through the germ line, and generated heterozygous offspring.  Germline 
transmission was confirmed by Southern blot assay from mouse tail DNA 
digested with Hind III restriction enzyme, and hybridized with probe 1 (figure 4).   
One ES clone was selected for blastocyst injection, of 8 chimeric mice obtained, 4 
transmitted ES cell DNA through the germ line and generated heterozygous 
offspring.  Germline transmission was demonstrated by Southern blot analysis of 
tail DNA (Figure 5B).  No abnormalities were observed in the F1 heterozygous 
animals in comparison to their wild type littermates. 
 
 
 
 
 
 
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Diagram the wild-type and the mutant alleles and of the Slc5a3 
(Smit1) targeting vector. PGK-neo, neomycin-resistant gene driven by 
phosphoglycerokinase gene promoter; Dtα, diphtheria toxin α-chain gene; ORF, 
open reading frame. 
 
 
 
 
 
 
24 
 
Mutant
Wild Type
Mutant
Wild Type
Wild Type
Mutant
A.
B.
C.
 
 
 
 
 
 
 
 
Figure 5.  Genotypic characterization of embryonic stem (ES) cells carrying the 
Slc5a3 mutant allele, and of Slc5a3 heterozygous mutant mice.  Southern  blot 
analyses of genomic DNA digested with HindIII enzyme,  hybridized with 32P-
labeled SacI fragment (probe 1 in figure 4). A.  Identification of ES clones that 
had undergone homologous recombination with the targeting vector.  Samples 
contained DNA isolated from G418 resistant ES clones. B.  Identification of 
Slc5a3 heterozygous mutant mice.  Samples contained tail DNA isolated  from a  
representative litter of  chimera X C57BL/6J mating. C. Identification of Slc5a3 
homozygous mutant embryos. Samples contained yolk sac DNA isolated from p. 
c. 18.5 day embryos generated from the mating of two Slc5a3 heterozygous 
mutant mice.  
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3.2 Prenatal detection of Slc5a3-null mutants  
To generate Slc5a3 knockout mice, generation 1 (F1) heterozygous males 
and females were bred and their offspring (generation 2, F2) were genotyped at 
weaning.  A total of 170 F2 mice were genotyped, 63 of them were Slc5a3 
wildtype and 107 Slc5a3 heterozygous. No Slc5a3 knockout mice were detected 
in the litters.  We performed caesarian sections on pregnant Slc5a3 heterozygous 
dams at day 18.5 post-coitus (pc).  At this stage all the embryos are viable.  We 
observed that the Slc5a3 knockout mice, contrarily to their wildtype and 
heterozygous siblings, failed to sustain breathing, to gain color, and ultimately 
became cyanotic and died within 20 minutes after birth.   No visible difference in 
size or in weight was observed in fetuses of all genotypes. 
3.3 Slc5a3 gene expression in wildtype, heterozygous and homozygous 
mice 
To confirm the absence of the Slc5a3 gene transcript as a direct 
consequence of the deletion of the Slc5a3 open reading frame (ORF) we 
performed Northern blot analyses using probe 2 in Figure 4.  We observed a 
~50% decrease in the Slc5a3 message in the brain tissue of heterozygous adult 
mice in comparison to the wildtype (Fig. 6A).  In placental tissues of embryonic 
mice, no Slc5a3 transcript was detected in the homozygous mutant sample, and a 
~50% decrease in the Slc5a3 message level is also seen in heterozygous sample 
(Fig. 6B). 
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Figure 6.   Slc5a3 gene expression in heterozygous, and homozygous wildtype 
and mutant tissues. Ablation of the Slc5a3 gene results in the decrease of the 
levels of its transcript. Each lane contained 30 µg of total RNA.  Hybridization 
was with a 32P-labeled Slc5a3 antisense riboprobe.   A.  Adult brain samples. B.   
Day 14.5 placental samples. 
 
 
3.4 Slc5a3 gene expression in adult and embryonic tissues 
To determine Slc5a3 expression in a variety of mouse tissues, a 32P 
radiolabeled probe  antisense to a sequence region within the open reading frame 
of the Slc5a3 was generated (probe2 in Figure 4),  and used to perform northern 
 WT  HZ   WT  KO HZ 
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blot hybridization analysis.  A total of 30 µg of RNA purified from mouse kidney, 
bladder, thynmus, lung, liver, intestine, spleen, ovary and uterus and placenta 
were analyzed.  A trascript of 11 Kb was detected in total RNA samples from all 
tissues analyzed.  High levels of expression were found in kidney, brain, testis and 
placenta, but no expression of the Slc5a3 was found either in heart nor in muscle 
tissues.  Poly adenylated RNA Nothern blot analysis (Fig2) shows that the 11 Kb 
transcript is the only detectable transcript showing that Slc5a3 is expressed as a 
single transcript.   
 
 
 
 
 
 
 
 
Figure 7. Expression of Slc5a3 in murine tissues.  A. Each tissue type 
contained 30 µg of total RNA isolated from adult mouse and placenta tissues.  
Hybridization was with 32P-labeled Slc5a3 antisense riboprobe.  B.  Ethidium 
bromide staining of the RNA gel before transferring, the 28s and 18s ribosomal 
RNA bands are indicated.  
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Figure 8.   Detection of Slc5a3 transcripts in total RNA and in polyA RNA 
from adult tissues and E14.5 embryo.  A. Total RNA from kidney and heart of an 
adult mouse, and poly A RNA from adult tissues and embryo. B. Ethidium 
bromide staining of the RNA gel before transferring, the 28s and 18s ribosomal 
RNA bands are indicated. 
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3.5 Myo-inositol measurement by GC/MS 
Gas chromatography/mass spectrometry was used to assess the degree of 
deficiency of myo-inositol in Slc5a3 gene knockout embryos at different stages of 
embryogenesis, at E10.5, E14.5 and E18.5.  Myo-inositol levels in these knockout 
embryos were then compared to concentration levels in wildtype littermates.  All 
the embryos analyzed were collected from two separate colonies: from pregnant 
mothers whose drinking water was supplemented with 1% myo-inositol 
throughout the gestational period, as well as from untreated expecting dams.   In 
brief, Slc5a3 heterozygous females were mated with Slc5a3 heterozygous males, 
and upon appearance of a vaginal plug in the impregnated female (day 0.5 p.c.), a 
set of female mice were placed on 1% myo-inositol-treated water for a gestational 
period interrupted at either day 10.5, 14.5 post-coitus to collect, respectively, 
E10.5 and E14.5 embryos, or at day 18.5 for the collection of E18.5 fetuses, while 
another set of impregnated female mice were left untreated for the same length of 
gestation.  At 10.5, 14.5, and at 18.5 p.c., all embryos were removed from their 
pregnant mothers, and immediately placed under liquid nitrogen.  The embryos’ 
tails were used for genotyping, except for the E10.5 embryos in which case the 
yolk sac was used to determine the genotype of each collected sample.  The 
frozen samples were processed at first for phosphatidylinositol measurements in a 
procedure outlined in the following chapter.  Myo-inositol measurements in the 
samples collected were carried out from the aqueous moiety derived from the 
partitioning of the organic-water phases that allowed separation of the 
hydrophobic inositol-lipids from the water soluble metabolites.  An aliquot of the 
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aqueous supernatant from all the samples was used for quantitative analysis of 
free myo-inositol by isotope dilution method by GC/MS utilizing an Agilent’s 
7890A/5975 GC/MS system.  An aliquot of the aqueous phase from the lipid 
organic extractions, containing the hexadeuterated stable isotope of myo-inositol 
([2H6]myo-inositol) as the internal standard added prior to the homogeneization of 
all tissues and used to quantify endogenous free myo-inositol,  was dried under a 
stream of nitrogen and derivatized with 50 µL BSTFA- 1% TMS and 5 of µL 
pyridine to convert myo-inositol, as well as the internal standard, to trimethylsilyl 
derivatives.  The derivatization of the samples was carried out overnight at 90oC, 
and then analyzed by GC/MS the following day.  Gas chromatographic separation 
was performed using a 30 m x 250 μm (i.d.) x 0.25 μm film HP-5MS column (J & 
W Scientific).  A volume of 1 μl derivatized extract was injected into the GC-MS 
using splitless mode. The column was kept at an initial temperature of 125°C for 
1 minute and increased to 150°C a the rate of 20°C/min, then ramped  to 215°C at 
a rate of 4°C/min, reaching final temperature of 300°C by 30°C/min , and kept at 
final temperature for 5 minutes.  Temperature for injector and detector was 250°C 
and 270°C, respectively.  Under these conditions, the retention times of hexa-
trimethylsilyl-myo-inositol and hexa-trimethylsilyl [2H6]myo-inositol were 9.834 
and 9.884 minutes, respectively.  Quantification of myo-inositol was performed in 
the single ion monitoring (SIM) mode[91], but full ion chromatograms were also 
obtained from each sample analyzed.   Prominent ion fragments at m/z 318 and 
m/z 321 observed for both compounds were monitored, and the integrated ion 
ratios m/z 318 (myo-inositol) to m/z 321 ([2H6]myo-inositol), were used for 
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quantification of myo-inositol.  Identification of myo-inositol was based on the 
comparison of retention time and mass fragmentation spectra with the standard 
compound.  Quantitative analysis of endogenous myo-inositol was performed by 
isotope dilution analysis based on the isotopic abundance the m/z 321 (that of 
[2H6]myo-inositol -TMS), and using a reference linear standard curve generated 
using a fixed amount of [2H6]myo-inositol added to increasing concentrations of 
myo-inositol.   
3.6 Myo-inositol in plasma of pregnant dams 
To evaluate plasma concentration of myo-inositol in the gestational time 
course of Slc5a3 carrier dams treated with myo-inositol, Slc5a3 carrier mice were 
mated, and upon detection of vaginal plugs to confirm mating and establish a 
timed pregnancy, pregnant dams were placed immediately on 1% myo-inositol.   
Blood (100 µL) from pregnant mice was collected in heparinized capillary tube 
by tail bleed. 25 µL of plasma was used for myo-inositol analysis, and following 
addition of 20 mM [2H6]myo-inositol internal standard the plasma was de-
proteinized  in two steps, first by addition of 25 µL of 0.3M barium hydroxide and 
by an equivalent of Zinc Sulfate, and later by addition of 400 µL of 
CH3OH:CHCl3 : 50:50 to clarify the supernatant.   
A 100 µL aliquot of the protein-free plasma was dried under a stream of nitrogen 
and derivitized with N,O-bis(trimethylsilyl) trifluoroacetamide / 
trimethylchlorosilane (BSTFA-1% TMCS, Sigma Aldrich, St. Louis, MO)  to 
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convert myo-inositol and the internal standard to trimethylsilyl derivatives and to 
be analyzed by GC/MS.   
Plasma was collected from of 5 treated and 5 untreated pregnant mice at three 
different stages of gestation at 0.5, 10.5, and 18.5 days post-coitus.   Myo-inositol 
plasma levels rise from 0.19 ±0.04 mM to a plateau level of 0.33 ± 0.04 mM  at 
gestational stage 10.5.   
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Figure 9 Total ion chromatogram (TIC) obtained from the analysis of hexa-
O-trimethylsilyl-myo-inositol  (Ins-TMS) from mouse plasma using the Agilent 
7890A/5975 GC/MS system equipped with an HP-5MS column (J & W 
Scientific). The red-circled peak corresponds to the Ins-TMS, along with TMS 
derivatives of other metabolites present in the sample.  The spectrum analysis was 
performed using ChemStation software from Agilent.  
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Figure 10.  Selected ion monitor (SIM) obtained from extraction of the two 
monitored ions m/z 318 (Ins-TMS) and m/z 321 ([2H6]Ins -TMS) from the TIC. 
Integration of the area of the two peaks is used to quantify the unknown 
endogenous myo-inositol against a known concentration of hexadeuterated myo-
inositol employed as an internal standard.  Analysis was performed using 
ChemStation software from Agilent. 
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Figure 11. Fragmentation of the myo-inositol-TMS derivative. The m/z 318 
ion was the monitored ion for SIM analysis of the derivatized myo-inositol 
compound and used for quantification.  The m/z 217 was also used as the 
qualifying ion in the analysis, performed using ChemStation software from 
Agilent. 
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3.7 Myo-inositol measurements data 
As shown in Table 1 and displayed in figure 13, myo-inositol 
measurements with a mean level of 0.10 ± 0.02 nmoles/mg (n = 5) in untreated 
E10.5 Slc5a3 knockout embryos show a 69.7% reduction compared to the mean 
levels of 0.33 ± 0.08 nmoles/mg (n = 5) in untreated Slc5a3 wildtype embryos, (p 
= 9.8E-05).  Physiological wildtype basal levels of myo-inositol are fully restored 
following 1% myo-inositol treatment of E10.5 knockout embryos with mean 
levels of 0.34 ± 0.05 nmoles/mg (n = 5),  (p = 0.41).   
Figure 14 displays myo-inositol levels in E14.5 wildtype and knockout 
embryos, with and without myo-inositol treatment. In knockout untreated E14.5 
embryos level of myo-inositol with a mean value of 0.50 ± 0.07 nmoles/mg (n = 
5) shows a marked reduction reduction of 71.9% in comparison to wildtype 
siblings with a mean value of 1.78 ± 0.16  nmoles/mg (n = 5) (p = 4.2E-07) .  
Levels of myo-inositol rise in knockout E14.5 embryos to a mean level of 0.65 ± 
0.03 nmoles/mg (n = 4) following myo-inositol treatment, although still markedly 
depressed when compared to basal levels in wildtype untreated embryos (p = 
4.1E-05).  
 Figure 15 displays myo-inositol levels in brains of E18.5 wildtype and 
knockout fetuses, with and without myo-inositol treatment.  In knockout untreated 
brains of E18.5 fetuses level of myo-inositol with a mean value of 0.25 ± 0.02 
nmoles / mg (n = 5) shows a reduction of  96.4%  in comparison to  wildtype 
littlermates with a mean value of 6.97 ± 0.48 nmoles / mg wet weight (n = 5) 
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(6.1E-10).  Levels of myo-inositol rise of 92.0% in brains of knockout E18.5 
fetuses to a mean level of 0.48 ± 0.03 nmoles / mg (n = 5) following myo-inositol 
treatment in comparison to levels in untreated knockouts (p = 3.3E-07), although 
still 73.0% lower than in myo-inositol levels in wildtype untreated embryos (p = 
8.1E-10).   
The mean myo-inositol levels in brains of adult wildtype and knockout 
mice at 12 weeks of age, following knockout ‘rescue’ with 1% myo-inositol until 
weaning age, 14 days after birth, are shown in Table 1 and in figure 16.  The 
mean myo-inositol level of 1.48 ± 0.82 nmoles/mg (n = 3) in untreated knockout 
adult brains was reduced by 70.1% compared to the mean level of 4.96 ± 0.82 
nmoles/mg (n = 3) in untreated wildtype adult mice, (p = 9.2E-04).   
Myo-inositol levels were also measured in plasma of pregnant dams fed 
with 1% myo-inositol (treated), and of untreated pregnant dams.  Plasma myo-
inositol levels reach a peak at day 10.5 post-coitus; as gestation progresses, levels 
of myo- inositol in plasma decreases due to perhaps increased clearance in the 
kidneys.  The mean myo-inositol levels in untreated pregnant dams at 0.5pc, 10.5 
p.c and 14.5 p.c. are, respectively, 0.12 ± 0.03 mM  (n = 3), 0.12 ± 0.04 mM  (n = 
3) and 0.12 ± 0.02 mM  (n = 3).  In myo-inositol treated dams the mean myo-
inositol levels 0.5pc, 10.5 p.c and 14.5 p.c are, respectively, 0.19 ± 0.04 mM  (n = 
3), 0.33 ± 0.04 mM  (n = 3), and 0.27 ± 0.02 mM  (n = 3). Plasma myo-inositol 
mean level rises significantly at 14.5 p.c. (p = 0.002) and at 18.5 p.c. (p = 0.002) 
in pregnant mice treated with 1% myo-inositol.  
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Figure 12.    Linear regression analysis used to quantify endogenous myo-inositol 
in E10.5 embryos generated with  increasing amounts of myo-inositol (0.25-1.5 
mM) in the presence of a fixed amount of [2H6]myo-inositol  (0.8mM), following 
isotope dilution analysis of the samples by GC/MS.  The ratios of the 
concentrations of Ins/ [2H6]myo-inositol were plotted against the ratios of the 
abundance of the two ion fragments m/z 318 (Ins), and 321 ([2H6]myo-inositol). 
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Table 1.   Myo-inositol levels in E10.5 and E14.5 mouse embryos, in brain of 
E18.5 fetuses, of untreated wildtype (WT) and knockout (KO) and 1% inositol-
treated wildtype (WT+) and knockout (KO+) tissues.  The table also lists levels of 
myo-inositol in brains of 12 weeks old “rescued” wildtype and knockout adult 
mice, WT (+) and KO (+),  whose inositol treatments ceased at weaning, 14 days 
post-natally.  
 
 
 
Weigths (mg) 
Mean ± SD 
 
nmol Ins/ mg weight 
Mean ± SD 
 
N 
 
 
E10.5 embryo       
WT  17 ± 4 0.33 ± 0.08 5 
KO 22 ± 5 0.10 ± 0.02a 5 
WT+ 13 ± 5 0.54 ± 0.12 5 
KO + 17 ± 5 0.34 ± 0.05 5 
E14.5 embryo       
WT  249 ± 24 1.78 ± 0.16 5 
KO 247 ± 40 0.50 ± 0.07a 5 
WT+ 205 ± 61 1.98± 0.35 5 
KO + 221 ± 20 0.65 ± 0.03 4 
E18.5 brain        
WT  79 ± 9 6.97 ± 0.48 5 
KO 78 ± 5 0.25 ± 0.02a 5 
WT+ 82 ± 2 7.34 ± 0.25 5 
KO + 70 ± 14 0.48 ± 0.03 5 
Adult brain        
WT (+) 210 ± 20 4.96 ± 0.82 4 
KO (+) 199 ± 22 1.48 ± 0.10a 4 
        
Ins in plasma of Slc5a3 HZ 
 pregnant dams mM    
    mean ± sd   
        
0.5 pc   0.12 ± 0.03 4 
10.5 pc   0.12 ± 0.04 4 
18.5 pc   0.12 ± 0.02 4 
0.5 pc, 1% Ins   0.19 ± 0.04 4 
10.5 pc, 1% Ins   0.33 ± 0.04b 4 
18.5 pc, 1% Ins   0.27 ± 0.02b 4 
 
ap < 0.05 comparing knockout to wildtype  
bp < 0.05  compating treated to untreated pregnant dams  
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Figure 13.   Myo-inositol content versus genotype in untreated wildtype and 
knockout (WT and KO), and 1% Ins-treated widtype and knockout (WT+ and 
KO+) E10.5 embryos.  Results are shown as means ± SD. Myo-inositol levels are 
69.7% reduced in knockout embryos (KO) (p= 9.8E-05), and restored in knockout 
embryos following 1% myo-inositol treatment (KO+) (p = 0.41). 
 
 
 
 
 
*
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
WT KO WT+ KO+
m
yo
-in
os
ito
l n
m
ol
es
 /m
g 
tis
su
e
Genotype
Myo-inositol levels in E10.5 embryos
41 
 
 
 
 
 
Figure 14.  Levels of myo-inositol in E14.5  fetuses versus genotype.  WT and 
KO are untreated wildtype and knockout fetuses, respectively, whereas WT+ and 
KO+ were collected from pregnant dams treated with 1% myo-inositol.  Results 
are shown as means ± SD. Myo-inositol levels are 71.9% reduced in knockout 
embryos (KO) (p= 4.2E-07) compared to wildtype littermates, and 63.5% reduced 
in knockout embryos following 1% myo-inositol treatment (KO+) (p = 4.1E-05). 
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Figure 15.   Levels of myo-inositol in brains of E18.5 fetuses versus genotype.  
WT and KO are untreated wildtype and knockout fetuses, respectively, whereas 
WT+ and KO+ were collected from pregnant dams treated with 1% myo-inositol.  
Results are shown as means ± SD.  Myo-inositol  mean level in brains of E18.5 
knockout fetuses, shows a 96.4% reduction  in comparison to mean level in 
wildtype littlermates (p =6.1E-10) and  a 92.0% increase in brains of myo-
inositol- treated knockout in comparison to the mean level in untreated knockout 
fetuses. Nevertheless, mean level of myo-inositol is still 73.0 % reduced in 
‘rescued’ E18.5 fetuses in comparison to mean level in wildtype untreated fetuses 
(p = 8.1E-10).   
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Figure 16.  Levels of myo-inositol in brains of 12 weeks old adult mice versus 
genotype.  WT (+) and KO (+) are “rescued” wildtype and knockout adult mice 
whose inositol treatments ceased at weaning, 14 days post-natally.  The mean 
myo-inositol level in brains of knockout adult is reduced by 70.1% compared to 
the mean level in wildtype adult mice (p = 9.2E-04).   
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Figure 17. Myo-inositol levels in plasma of pregnant and dams treated and 
untreated.  Blood was collected at day of detection of vaginal plugs (day 0.5 post 
coitus) in dams that were mated with Slc5a carrier males, at day 10.5 p.c. and at 
day 18.5 p.c. Myo-inositol mean level in plasma rises significantly at 14.5 p.c. (p 
= 0.002) and at 18.5 p.c. (p = 0.002) in pregnant mice treated with 1% myo-
inositol. 
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3.8 Measurement of phosphatidylinositol by MALDI-TOF MS  
3.8.1 PtdIns levels in tissues of mutant newborn and adult mice 
For the analysis of PtdIns in E14.5, and E18.5 Slc5a3 wildtype and null 
mutants, Slc5a3 heterozygous dams were mated with Slc5a3 heterozygous males, 
and upon appearance of a vaginal plug in the impregnated females (set as day 0.5 
post-coitus), a group of dams were placed on 1% myo-inositol-enriched water for 
a gestational period interrupted at either day 14.5 post-coitus (pc) to collect E14.5 
embryos, or at day 18.5 pc for the collection of E18.5 fetuses. A separate set of 
control impregnated female mice were left untreated for the same length of 
gestation.  At day 14.5 pc all embryos were collected, and at day 18.5 pc fetuses 
were removed, and their brains dissected out.  All the samples collected were 
immediately placed under liquid nitrogen.  Tails snips from the embryos were 
used for genotyping.  E18.5 brain, E14.5 whole embryo, and adult brain tissues 
(all except E10.5 embryos) of each genotype, wildtype and knockout, either myo-
inositol-treated or -untreated, were homogenized and processed for lipid isolation 
using a modified extraction procedure described by Bligh and Dyer [17] and 
Schacht [18] in which the organic extraction solvent takes into account the water 
content in each sample. 
All tissues were disrupted by mechanical homogeneization in 700 µL of 
extraction solvent CHCl3:CH3OH:H2O:conc.HCl 10:20:7:1, following addition of 
a fixed amount of the soybean phosphatidylinositol internal standard in proportion 
to the type of  murine tissue  sampled, as to maintain equivalent concentrations of 
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the internal standard and of the endogenous mammalian phosphatidylinositol.  
Each sample homogenate was transferred to a glass centrifuge tube, and lipids 
were isolated by phase partitioning following addition of 200 µL CHCl3 and 
200 µL of H2O.  The two phases, the aqueous layer containing water soluble 
metabolites, and the lower lipophilic organic layer were separated by 
centrifugation.   The organic bed was recovered and washed twice with 1.5 
volumes of  CH3OH:H2O:conc.HCl, 20:19:1,  then passed through a strong cation 
exchange column,  a 1.0-ml column of RediSep SCX resin (Teledyne Isco, 
Lincoln, NE) packed in a glass-wool-plugged Pasteur pipette,  for removal of  
cationic lipids such as phosphatidylcholine.     Prior to use, the column was 
washed/regenerated with freshly mixed acetonitrile/1 M HCl , and equilibrated in 
CHCl3:CH3OH:H2O, 20:9:1 [19–21].    The lipidic flow-through fraction was 
collected, and dried thoroughly under a stream of N2.   
The lipid liquor was redissolved in 20 µL of CHCl3:CH3OH, 50:50, containing 
0.5 M of the matrix 2,5-Dihydroxybenzoic acid (DHB, Sigma Aldrich, St. Louis, 
MO) used for mass spectrometric analysis. 0.2 µL of the lipid-DHB mixture was 
spotted on a MALDI-TOF target slide.    Mass spectrometry measurements were 
carried out  at -20 kV in the reflectron negative by selective accumulation using 
an Ettan MALDI-TOF/Pro (GE Healthcare, Piscataway,NJ). The low mass 
rejection was set to m/z 500 and the focus mass to m/z 1000.  Soybean 
phosphatidylinositol, the internal standard, has a predicted molecular ion peak at 
m/z 833.5, corresponding to the 16:0-18:2 phosphatidylinositol species (figure 
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18).  The intensity of this ion was used for quantitative analysis of the endogenous 
murine  18:0-20:4 phosphatidylinositol species  (figure 19) with predicted ion 
peak at m/z 885.5.    
To quantify the mammalian 18:0-20:4 phosphatidylinositol in the samples, 
an analytical standard curve was generated in which known amounts of bovine 
brain phosphatidylinositol (whose composition is identical to that of mouse 
phosphatidylinositol) were mixed with a fixed amount of soybean 
phosphatidylinositol and analyzed by MALDI-TOF MS.  The murine  
phosphatidylinositol concentration was calculated by regression analysis.   
3.8.2 Measurement of PtdIns levels in E10.5 embryos 
For the analysis of PtdIns in E10.5 Slc5a3 wildtype and null mutants, 
Slc5a3 heterozygous mice were mated, and upon detection of a vaginal plug in the 
impregnated females, a set of female mice was placed on 1% myo- inositol-treated 
water for a gestational period interrupted at day 10.5 post-coitus, while another set 
of impregnated female mice was left untreated for the same length of gestation.  
At E10.5 all embryos, along with their yolk sacs, were removed from their 
pregnant mother, separated from their yolk sacs, washed three times in sterile 
PBS, labeled, and immediately placed under liquid nitrogen.  The embryos yolk 
sacs were used to genotype the collected embryos.   
Each frozen embryo was weighed, and placed in 1.5 mL microfuge tube 
containing 5 µL of a 5 mg/ml of Soybean PtdIns, the internal standard, and kept 
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on wet ice to minimize complete thawing of the sample.  200 µL of sterile 
phosphate buffer saline (PBS) were added to each sample following addition of   
7.5 µL of 1 mM [2H6]myo-inositol (hexadeuterated myo-inositol), the myo-inositol 
internal standard. E10.5 embryos were sonicated and spun at max speed for 10 
minutes in a refrigerated microcentrifuge. Following centrifugation a 20 µL 
aliquot of the clear supernatant was subtracted from each sample for protein 
assay, while the pellet is processed for myo-inositol and PtdIns analysis by 
addition of 700 µL of the organic extraction buffer CHCl3:CH3OH:HCl:H20, 
10:20:1:3.  Each  sample was vigorously vortexed at room temperature  for 
complete solubilization of the lipid components into the organic moiety.  
Fractionation of lipids and water-soluble metabolites, including myo-inositol, was 
achieved by addition of 200 µL CHCl3 and 200 µL of H2O. Following vigorous 
mixing, the samples were spun at maximum speed at room temperature to allow 
separation of the organic and aqueous phases.   The bottom organic phase was 
recovered and dried under a stream of N2 and processed for PtdIns analysis by 
MALDI-TOF MS.  100 µL of the CHCl3- washed aqueous supernatant was used 
for myo-inositol quantitative analysis by GC/MS. 
The organic phase was washed twice with 1.5 volumes of CH3OH:H2O:TFA, 
20:9:0.1% (v/v), and dried under a stream of nitrogen.  The lipid liquor was 
redissolved in 40 µL of CHCl3:CH3OH:TFA, 1:3:0.1% (v/v) (approximate final 
concentration of 2.5 to 10 µg lipid/µl of CHCl3) and de-cationized by reversed-
phase chromatography using ZipTip strong cation exchange (SCX) Pipette Tips 
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(10 µL) (Millipore, Billerica, MA).  Binding of positively charged lipids to the 
SCX chromatography media was carried out by drawing and releasing the lipid 
solution about fifty times.  For MALDI-TOF MS analisys of PtdIns, 2.5 µL of the 
lipid solution was mixed with 5 µL of 0.5 M 2,5-dihydroxybenzoic acid (DHB) 
matrix solution dissolved in CH3Cl:CH3OH, 50:50.   
Analysis of Phosphatidylinositol from E10.5 embryos was performed by mass 
spectrometry at the Dana Farber Cancer Institute in Boston (MA) using a 4800 
Plus MALDI TOF/TOF MS Analyzer (Applied Biosystems, Foster City, CA). 
Sample ionization was induced by a 337-nm pulsed nitrogen laser, and the 
extraction voltage was set at -20 kV. The laser power was adjusted to obtain a 
high signal-to-noise ratio (S/N), and the low gate limit was set to m/z 600. This 
low-mass cut off was purposely set to allow the detection of the fragment at m/z 
833.5 and m/z 885.5 which correspond to the protonated form of soybean 
phosphatidylinositol and mammalian phosphatidylinositol, respectively.  An Opti-
TOF® stainless-steel sample plate with 13 calibration points from Applied 
Biosystems was used.  The small size of the wells reduced the volume of sample 
and matrix spots and led to rapid evaporation of the solvents. 0.2 µL of the 
Lipid:DHB mixture was “spotted” onto the plate. After crystallization under 
ambient conditions, negative-ion spectra were acquired in the reflector mode. 
Each mass spectrum represented the average of more than 1500 shot 
accumulations.   Qualitative analysis of PtdIns peaks was performed using Data 
Explorer® software from Applied Biosystems.  
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Soybean phosphatidylinositol was used as the internal standard, and its predicted 
molecular ion peak is at m/z 833.5, corresponding to the soybean 16:0-18:2 
phosphatidylinositol, and the intensity of this selected peak was used to quantify 
the level of endogenous 18:0-20:4 phosphatidylinositol species in the E10.5 
samples with  predicted ion peak at m/z 885.5.    
For quantification of the mammalian 18:0-20:4 phosphatidylinositol in the 
samples, an analytical standard curve was generated in which known amounts of 
bovine brain phosphatidylinositol (whose composition is identical to that of 
mouse phosphatidylinositol) was mixed with a fixed amount of soybean 
phosphatidylinositol and analyzed by MALDI-TOF/MS.  The murine  
phosphatidylinositol concentration was calculated by regression analysis.  
 
 
 
 
 
Figure 18.  16:0-18:2 phosphatidylinositol (soybean phosphatidylinositol), 
m/z 833.5 (deprotonated form shown) 
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Figure 19. 18:0-20:4 phosphatidylinositol (mammalian phosphatidylinositol), 
m/z 885.5 (deprotonated form shown).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 MALDI-TOF MS negative-ion spectrum acquired in the reflector 
mode of lipid extract fractions from an E10.5 wildtype embryo. The lipid extract 
was prepared and then fractionated using ZipTip® strong cation exchange (SCX) 
Pipette Tips (10 µL) from Millipore as described in the text. 
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3.8.3  PtdIns measurements data 
Table 2 shows the measurements of PtdIns in E10.5 and E14.5 embryos, 
in brains of E18.5 fetuses (Figures 22,23, and 24) in both myo-inositol-treated and 
–untreated samples,  and  brains of adult wildtype and knockout mice at 12 weeks 
of age, following knockout ‘rescue’ with 1% myo-inositol until weaning age, 14 
days after birth adult brains (Figure 25).  In E10.5 embryos, as pictured in figure 
22, the mean PtdIns level of 0.50 ± 0.15 µg/mg (n = 5) in untreated knockout 
fetuses show a remarkable 47% decrease from the physiological mean PtdIns 
level of 0.95 ± 0.16 µg/mg /mg (n = 5) in untreated wildtype embryos (p 
=0.0035). PtdIns levels are fully restored in knockout embryos following inositol 
treatement to a mean level of 0.88 ± 0.13 µg/mg /mg (n = 5), (p = 0.24).   
In brains of E18.5 fetuses, the mean PtdIns level of 0.90 ± 0.10 µg/mg (n 
= 5) in untreated knockout fetuses was also not different than the mean PtdIns 
level of 0.98 ± 0.22 µg/mg (n = 5) in untreated wildtype fetuses (p = 0.08). The 
mean PtdIns level of 0.99 ± 0.08 µg/mg /mg (n = 5) in brains of Ins-treated E18.5 
knockout fetuses was not different than the mean PtdIns level in untreated 
knockout fetuses (p = 0.31).  
The mean PtdIns level of 1.00 ± 0.13 µg/mg /mg (n = 5) in untreated 
E14.5 knockout embryos is not different than the mean PtdIns level of 0.98 ± 0.10 
µg/mg (n = 5) in untreated wildtype fetuses (p = 0.33).  The mean PtdIns level of 
1.04 ± 0.07 µg/mg (n = 4) in myo-inositol-treated E14.5 knockout embryos is not 
different than in untreated wildtype embryos (p = 0.11). 
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The mean PtdIns level of 1.75 ± 0.36 µg/mg /mg (n = 3) in brains of adult 
‘rescued’ knockout mice is not different than the PtdIns level of 2.09 ± 0.42 
µg/mg (n = 3) in brains of adult wildtype mice (p = 0.22).   
 
 
 
 
 
 
 
 
 
Figure 21 Linear regression analysis used to quantify endogenous (18:1-20:4) 
phosphatidylinositol in E10.5 embryos by MALDI-TOF mass spectrometric 
analysis.  The graph was generated following mixing of fixed amount of (16:0-
18:2) phosphatidylinositol-soybean PtdIns (16 µg), equal to the amount added as 
internal standard in each sample, with  increasing amounts of standard myo-
inositol (2-20 µg).  The ratio of the concentrations of the two PtdIns in each 
sample was plotted against the ratio abundance of the ion fragments m/z 885.5 
(mammalian PtdIns), and m/z 833.5 (Soybean PtdIns).  
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Table 2. PtdIns mean levels quantified by MALDI-TOF MS in E10.5 and 
E14.5 mouse embryos, in brains of E18.5 fetuses  in both myo-inositol-treated and 
–untreated samples,  and  brains of adult wildtype and knockout mice at 12 weeks 
of age, following knockout ‘rescue’ with 1% myo-inositol until weaning age, 14 
days after birth.   
        
  Weigths (mg) µg PtdIns/ mg weight N 
  Mean ± SD Mean ± SD   
        
E10.5 embryo       
WT  17 ± 4 0.95 ± 0.16 5 
KO 22 ± 5 0.50 ± 0.15a 5 
WT+ 13 ± 5 0.83 ± 0.09 5 
KO + 17 ± 5 0.88 ± 0.13 5 
E14.5 embryo       
WT  249 ± 24 0.98± 0.10 5 
KO 247 ± 40 1.00 ± 0.13 5 
WT+ 205 ± 61 0.96 ± 0.07 5 
KO + 221 ± 20 1.04 ± 0.07 4 
E18.5 brain        
WT  79 ± 9 0.98 ± 0.22 5 
KO 78 ± 5 0.90 ± 0.10 5 
WT+ 82 ± 2 0.99 ± 0.08 5 
KO + 70 ± 14 0.82 ± 0.29 5 
Adult brain        
WT (+) 210 ± 20 2.09 ± 0.42 4 
KO (+) 199 ± 22 1.75 ±  0.36 4 
 
a p < 0.05 comparing knockout to wildtype  
 
 
 
55 
 
 
 
 
 
 
 
Figure 22. PtdIns measurements levels in wildtype and knockout E10.5 
embryos (WT, KO), and in 1% inositol-treated E10.5 littermates (WT+, KO+).  
As displayed on the graph, PtdIns is reduced by 49% in knockout treated embryos 
(p =0.0035), whereas is normalized in knockout embryos following treatment (p = 
0.24).   
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Figure 23. PtdIns measurements levels in wildtype and knockout E14.5 
embryos (WT, KO), and in 1% myo-inositol-treated E10.5 littermates (WT+, 
KO+).  No difference in mean level of PtdIns is observed between wildtype and 
untreated knockout embryos (p = 0.33), and between wildtype and knockout 
treated embryos (p = 0.11). 
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Figure 24. PtdIns measurements levels in brains of wildtype and knockout 
E18.5 fetuses (WT, KO), and in 1% myo-inositol-treated E18.5 littermates (WT+, 
KO+).  No difference in mean level of PtdIns is observed between wildtype and 
untreated knockout fetuses (p = 0.08), and between wildtype and knockout treated 
(p = 0.31). 
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Figure 25. PtdIns measurements levels in brains of 12 weeks old adult mice , 
wildtype and knockout littermates ‘rescued’ by myo-inositol-treatment (WT(+), 
KO(+)).  No difference in mean level of PtdIns is observed between wildtype and 
‘rescued’ knockout adult mice (p = 0.22).  
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3.9 Quantification of the inositol polypolyphosphates InsP5 and InsP6 
The mass determinations of the inositol polyphosphates, myo-inositol-
1,3,4,5,6-P5 (InsP5) and myo-inositol-1,2,3,4,5,6-P6 (InsP6)in brains of E18.5 
wildtype and knockout fetuses were determined based on methods described by 
Mayr [92].   Brains were homogenized in buffer containing NaF and EDTA, and 
deproteinized with perchloric acid (PCA).  KOH (4 M) was added to pH 5 -6 to 
precipitate the PCA.  The myo-inositol polyphosphates were separated by anion 
exchange HPLC on a MonoQ® column (GE Healthcare, Piscataway, NJ) 
collected in fractions, and quantified colorimetrically by addition of yttrium, and 
4-(2-pyridylazo) resorcinol (PAR) and read spectrophotometrically at OD520.  
The assay was standardized using commercial InsP6 (phytic acid).  In separate 
experiments, the InsP5and InsP6peaks co-eluted with spikes of known InsP5 and 
InsP6, respectively.  
3.9.1 InsP5 and InsP6 measurement data 
As shown in figure 26, InsP5 and InsP6 levels are comparable in the three 
genotypes. Phytase treatment eliminated both the InsP5 and InsP6 peaks from the 
elution profile. The levels of InsP5 are 29.2 ± 0.8, 27.9 ± 2.7 and 30.8 ± 2.4 
pmol/mg in wildtype, heterozygous and knockout brain tissues, respectively. The 
levels of InsP6 are 26.0 ± 0.6, 25.1 ± 2.9 and 25.8 ± 3.7 pmol/mg in wildtype, 
heterozygous and knockout tissues, respectively. These results show that the 
levels of the myo-inositol containing metabolites, InsP5 and InsP6, are normal at 
the time of birth even when myo-inositol levels are severely depressed. 
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Furthermore, the myo-inositol ring structure derived from alkaline phosphatase-
treated InsP6 appeared to be entirely myo-inositol based on GC/MS results 
showing an elution profile and mass spectrometry fragments which were identical 
with a myo-inositol standard (data not shown). 
 
 
 
 
 
 
Figure 26. Levels of InsP5 and InsP6 from wiltype, heterozygous and 
knockout  E18.5 fetal brains.  
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3.10 Effect of Slc5a3 deletion on lung parenchymal ultrastructure, 
surfactant protein and phospholipid production 
To assess the possibility that deficiency of phospholipid synthesis in lungs 
of Slc5a3-null newborns plays a role in their post-natal respiratory failure, we 
studied lung surfactant production in E18.5 homozygous mutant fetuses.  
Surfactant is a lipo-protein complex, highly abundant in the air-liquid interface of 
the alveolar surface of the lungs, and plays a function of preventing alveolar 
collapse during breathing cycle.   These studies were performed with the 
collaboration of Drs. Linda Gonzales and P. Ballard at Children’s Hospital of 
Philadelphia, PA. 
3.10.1 Precursor incorporation and phospholipid (PL) analysis      
Lungs of E18.5 knockout and wildtype fetuses were removed and placed 
in sterile PBS on ice, and each fetal lung was dissected out.  Of the 3 lobes on the 
right side, one was fixed for EM, one for immunostaining, and the third (largest) 
was cultured for phospholipid labeling. Of the 2 lobes on the left side, one was 
frozen (-70oC) for later use, and one (larger) was cultured for [3H] acetate 
incorporation into phospholipids.  Lung explants were immersed in 250 µl of 
Waymouth’s media with either 7 µM myo-[2-
3
H] inositol (10 µCi/ml), or 1 mM 
of [3H] acetate (20 µCi/ml) and rocked for 5 h at 3 cycles/min in a 37oC 
humidified incubator.  Following incubation, the tissues were harvested into cold 
PBS, then sonicated in saline, and assayed for protein.  To determine 
phospholipid composition, total lipid extracts were separated by thin-layer 
chromatography (TLC)[93].  The aqueous fraction from the lipid extraction was 
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counted to determine myo-inositol intracellular uptake.  As shown in figure 27, 
there was a reduced incorporation of myo-[2-3H] inositol into 
phosphatidylinositol, but a comparable amount of [3H]-acetate labeling of 
phospahtidylinositol was detected in the tissue from knockout fetuses compared to 
wildtype littermates (figure 27).  There were no other differences in PL 
composition or synthesis (figure 28). 
 
 
 
Figure 27. Incorporation of myo-[2-3H]-inositol and 3H-acetate into PtdIns in 
lung explants of E18.5 knockout and wildtype fetuses. 
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Figure 28. Incorporation of [3H]-acetate into Lyso-phoshatidylcholine (Lyso-
PC), Sphingomyelin (SPH), Phosphatidylcholine (PC), Phosphatidylserine (PS), 
Phosphatidylinositol (PI), Phosphatidylethanolamine (PE) and 
Phosphatidylglycerol (PG) in lungs explants of E18.5 knockout and wildtype 
fetuses.   
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3.11 Cell morphology and immunostaining of Slc5a3 knockout lung 
explants 
3.11.1 Electron microscopy of lung explants  
Lungs explants from knock E18.5 fetuses were fixed in 2.5% glutaraldehyde, 0.1 
M sodium cacodylate (pH 7.2) for 3 h at 40 C, washed, and post-fixed with 1% 
osmium tetroxide[94].  The tissue was embedded in epoxy resin, and ultrathin 
sections were contrasted with uranyl acetate and lead citrate, and examined in a 
JEOL CX100II transmission electron microscope operated at 80 kV.  Cells from 2 
lungs of each group were examined (4 sections/sample).  The type 2 pneumocytes 
in knockout fetuses show no morphologic abnormalities and the surfactant-
containing lamellar bodies appear normal (figure 29). 
3.11.2 Immunocytochemistry of lung tissue  
  To prepare frozen lung  tissue sections for immunofluorescence, lobes 
were fixed in 1% paraformaldehyde in PBS overnight at 4oC, washed with PBS  
for 5 min  and embedded in OTC freezing medium .  Cut sections were washed 
with sodium borohydride (0.1% in PBS) to reduce autofluorescence, and rinsed 
twice with PBS.   Sections were incubated (30 min, 25oC ) in PBS containing 
0.3%  Triton X-100 , 5% BSA and  10% normal goat serum to block nonspecific 
binding and permeabilize cells, followed by 5 min wash with 0.3%Triton X-100 
in PBS.  Coverslips were incubated with primary antibodies overnight at 4oC.  
Antibodies used were: rabbit anti-human SP-A (polyclonal, gift of M. Beers, U. 
Penn,), anti-bovine SP-B (polyclonal prepared against SP-B extracted from 
surfactant TA, gift from M. Beers, U. Penn.), and anti-rat SP-C.   To remove 
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excess antibody, slides were incubated with 0.3%Triton X-100 in PBS for 5 
minutes.   
Primary antibodies were detected by addition of secondary antibody (goat 
anti-rabbit IgG conjugated to Cy3, 1: 200) for 1 h at 25oC.  Excess secondary 
antibody was removed by washing the slides  with 0.3% Triton X-100 in PBS, 
then PBS plus 0.075% Triton X-100, and finally with PBS alone.   Coverslips 
were air-dried and mounted with Mowiol (Calbiochem, San Diego, CA). 
Fluorescence was examined with an Olympus 1X70 microscope and Metamorph 
imaging system. No lesions were identified in immunohistochemical stains of the 
type 2 pneumocytes in knockout fetuses. The content of surfactant proteins A,B, 
and C in Slc5a3 knockout fetuses were comparable to control wildtype fetuses. 
In summary, there is no evidence of type 2 pneumocytes with abnormalities in 
cellular architecture, surfactant structure or secretion despite the fact that the lung 
tissue slices from E18.5knockout fetuses manifest reduced myo-(2-3H)inositol 
uptake into PtdIns. As for the 3H-acetate labeling, incorporation into PtdIns is 
comprable to wildtype fetuses, the data suggest that reduced Ins transport into 
lung cells does not limit PtdIns synthesis. There is no evidence for a primary 
problem in the lungs of the newborn wildtype fetus. 
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Figure 29.  Electron microscopy of type 2 pneumocytes from  lung explants 
of an E18.5 Slc5a3 knockout fetus. 
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3.12 Electrophysiological studies of viable E18.5 fetuses 
The Slc5a3 knockout phenotype is lethal.  Homozygous mutant newborns die 
shortly after birth due to an aberrant respiratory rhythm.  To test the 
hypoventilation hypothesis as the primary reason that leads to respiratory arrest at 
birth in Slc5a3 knockout mice, we performed recordings of inspiratory neuronal 
discharge in the brainstem of wildtype and knockout E18.5 fetuses in 
collaboration with Dr. John Greer, a principal investigator in the department of 
Physiology in Centre for Neuroscience and Perinatal Research Centre at the 
University of Alberta, Canada.   
In mammals, respiratory rhythm is generated by a cluster of neurons 
(pacemaker cells) that populate a defined area in the ventrolateral medulla of the 
brainstem referred to as the pre-Bötzinger Complex[95] .   To examine the 
inspiratory drive transmission from the ventrolateral medulla to respiratory 
motoneurons, thus to phrenic motoneurons, we performed electrophysiology 
studies to inspect central respiratory rhythmogenesis and synaptic drive on 
brainstem spinal cord and medullary slice preparations of Slc5a3 homozygous 
mutant E18.5 fetuses.   
In homozygous mutant fetuses there are 3-8 apneic episodes of 15-60s 
duration per a 10-min period, and that the periods of suppressed respiratory 
rhythmic discharge alternated with bouts of rhythmic respiratory bursting of much 
higher frequency than in wild type preparations. 
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3.12.1 Brain stem-spinal cord preparations 
For brain stem-spinal cord preparations Slc5a3 wildtype and knockout 
E18.5 fetuses were removed by caesarean sections from timed-pregnant mothers  
anesthetized with halothane (1.25-1.5% delivered in 95%02 and 5%CO2), and 
maintained at 37oC by radiant heat.  The timing of pregnancies of dams was 
determined from the appearance of vaginal plugs.  Immediately upon delivery, the 
fetuses were decerebrated , and the neuraxis isolated by dissection and bathed in 
artificial cerebrospinal fluid that contained 128 mM NaCl, 3.0 mM KCL, 1.5 mM 
CaCl2, 1.0 mM MgSO4, 24 mM NaHCO3, 0.5 mM NaH2PO4, and 30 mM  D-
glucose equilibrated with 95% O2 – 5%CO2 at 27°C (pH=7.4).   Recordings of 
cranial (X,XII) and spinal (C4 and T2-4) motoneuron activity in vitro were made 
with suction electrodes applied to the cut ends of cranial nerves and spinal ventral 
roots.  Signals were amplified, rectified, low-passed filtered and recorded via 
pulse code modulation (Vetter model 3000A) via an analogue-digital converter 
(DigiData 1200, Axon Instruments) and data acquisition software (Axotape, Axon 
Instruments).  
3.12.2 Electrophysiological recordings data stem-spinal cord preparations 
As shown in figure 30, the drawing on the upper left of the figure depicts 
the brainstem and spinal cord preparation from the diaphragm connected via the 
phrenic nerve.  In A, the inspiratory rhythm is continuous and regular in wildtype 
preparation.  In B, in contrasts, Slc5a3 knockout preparations all have very 
irregular respiratory rhythm patterns with several defining features.  There are 3-8 
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apneas of 15-60s duration per 10 min period.  Overall, the interburst interval in 
Slc5a3 preparations (7.8+/- 8.1 s) is significantly longer than in Slc5a3 wildtype 
preparations (4.3+/-2.4 s).  As shown in C, the periods of suppressed respiratory 
rhythmic discharge are interspersed with bouts of rhythmic respiratory bursting of 
much higher frequency (interburst interval of 1.4+/- 0.5 s) than observed in 
wildtype preparations. Also, there are regular occurrences of augmented breaths 
that are of larger amplitude and slightly longer duration. As shown in D, the 
duration and amplitude of rectified and integrated inspiratory bursts (other than 
augmented bursts) in Slc5a3 knockout preparations are about 65% of those 
observed for wildtype preparations. 
Figure 31 shows the effect of myo-inositol administration (1 mM) on the  
the frequency, amplitude and regularity of rhythms generated by wildtype and 
knockout E18.5 Slc5a3 fetuses mouse medulla–spinal cord preparations. No 
differences in the electrophysiological recordings of spinal cord preparation were 
observed upon bathing following exposure to 1mM  of myo-inositol in the bathing 
media. (A) Representative recordings of rectified and integrated diaphragm 
electromyography (EMG) from in vitro preparations isolated from E18.5 wildtype 
and knockout in vitro preparations in response to bath application of myo-inositol 
(time course indicated by horizontal line).  Population data for mean frequency 
(B) and coefficient of variability (C) of inspiratory bursts generated by WT and 
KO preparations.  Each data point is from six preparations. 
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3.12.3 Medullary slice preparation 
Medullary slice preparation containing the pre-Bötzinger complex and 
hypoglossal motor nerves (XII) were obtained from dissected brains of Slc5a3 
wildtype and knockout E18.5 fetuses.   
The methodology for preparing the medullary slice has been previously 
described[95, 96] .  Briefly, fetal mice were decerebrated and the neuraxis 
isolated by dissection as described for Brain stem-spinal cord preparations.  The 
brain stem-spinal cord was pinned down, ventral surface upward, on a paraffin-
coated block.  The block was mounted in the vise of a vibratome bath (Leica) and 
sectioned serially in the transverse plane starting from the rostral medulla to 
within ~200 µm of the rostral boundary of the pre-Bötzinger complex, as judged 
by the appearance of the inferior olive.  A single transverse slice containing the 
pre-Bötzinger complex and more caudal reticular formation regions was cut (500-
600 µm thick), transferred to a recording chamber and pinned down onto a 
Sylgard elastomer.  The medullary slice was bathed in physiological solution 
similar to that used for the brain stem-spinal cord preparation.  Respiratory 
motoneuron activities were recorded with suction electrodes applied to cut ends of 
XII nerve roots.  
3.12.4 Electrophysiological recordings from medullary slice preparations  
Figure 32 shows respiratory motor discharge traces recorded bilaterally 
from hypoglossal nerve roots (lower), and whole-cell recording from the 
rhythmically active neurons in pre-Botzinger complex (upper).  In A, recording of 
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inspiratory neuronal discharge in medullary slices isolated from E18.5 wildtype 
fetus. In B, direct recordings of neuronal population discharge within the PBC 
demonstrate that the irregular rhythms are present in the putative respiratory 
rhythm generating center, the pre-Bötzinger complex (PBC), of Slc5a3 knockout 
E18.5 fetuses.  C shows the duration and amplitude of rectified and integrated 
motor discharge are decreased in knockout as compared to wildtype preparations. 
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Figure 30. Recordings of rectified and integrated diaphragms 
electromyography (EMG) from in vitro preparations isolated from E18.5 fetuses.  
In A, the inspiratory rhythm is continuous and regular in wildtype preparation.  In 
B, in contrasts, Slc5a3 knockout preparations all have very irregular respiratory 
rhythm patterns with several defining features.  There are 3-8 apneas of 15-60s 
duration per 10 min period.  Overall, the interburst interval in Slc5a3 preparations 
(7.8+/- 8.1 s) is significantly longer than in Slc5a3 wildtype preparations (4.3+/-
2.4 s).  As shown in C, the periods of suppressed respiratory rhythmic discharge 
are interspersed with bouts of rhythmic respiratory bursting of much higher 
frequency (interburst interval of 1.4+/- 0.5 s) than observed in wildtype 
preparations. As shown in D, the duration and amplitude of rectified and 
integrated inspiratory bursts (other than augmented bursts) in Slc5a3 knockout 
preparations are about 65% of those observed for wildtype preparations. 
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Figure 31. Myo-inositol administration (1 mM) did not affect the frequency, 
amplitude and regularity of rhythms generated by wildtype and knockout E18.5 
Slc5a3 fetuses mouse medulla–spinal cord preparations. (A) Representative 
recordings of rectified and integrated diaphragm electromyography (EMG) from 
in vitro preparations isolated from E18.5 WT and KO in vitro preparations in 
response to bath application of myo-inositol (time course indicated by horizontal 
line; 0.1–1 mM Ins solutions). Population data for mean frequency (B) and 
coefficient of variability (C) of inspiratory bursts generated by WT and KO 
preparations. * indicates p < 0.05, significant difference between the groups 
compared. Each data point is from six preparations. 
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Figure 32.  Rhythmic activity of a medullary slice (500 µm thick) containing 
the pre-Botzinger complex (PBC), and the hypoglossal nucleus (XII). In A, 
recording of inspiratory neuronal discharge in medullary slices isolated from 
E18.5 wildtype fetus. In B, direct recordings of neuronal population discharge 
within the PBC demonstrate that the irregular rhythms are present in the putative 
respiratory rhythm generating center, the pre-Bötzinger complex (PBC), of Slc5a3 
knockout E18.5 fetuses.  C shows the duration and amplitude of rectified and 
integrated motor discharge are decreased in knockout as compared to wildtype 
preparations 
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3.12.5 Ultra-structural analysis of synapses of preBötC neurons by EM. 
The rationale to perform ultrastructural analysis of synapses of preBötC 
neurons by electron microscopy on brain tissue preparations  of Slc5a3 knockout 
E18.5 fetuses came from the observation that Slc5a3 mutant newborns die of 
congenital hypoventilation, finding supported by electrophysiological aberrations 
in the respiratory brain center upon examinations of knockout newborn fetuses, as 
shown in the previous section.  Another plausible explanation for EM analysis of 
the respiratory pacemaken center in the ventromedullary region of the lower 
brainstem of E18.5 knockout was driven by the finding that neuronal 
development, or partial development of phrenic nerves essential in the activation 
of the diaphragm muscle was normal following immunohistochemical staining; 
hence excluding morphological dysfunction and the leading cause of impaired 
central regulation of breathing in the mutant model as the cause of death post 
partum.  Ultra-structural analysis of synapses of preBötC neurons reveals no 
changes in SLc5a3 KO mice. 
Analysis of the the ultrastructure of synapses in the preBötC area of Slc5a3 knock 
out fetuses and found that knockout neurons form synapses that contain 
presynaptic vesicles, large dense core vesicles and docked vesicles (Figure 32).  
Moreover, knockout synapses display comparable synaptic clefts, postsynaptic 
densities and similar densities of synaptic vesicles in the vicinity of the 
presynaptic membrane. Thus, these data indicate that the pronounced functional 
synaptic phenotype in Slc5a3 knockout mice can neither be simply explained by 
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synaptic malformation.  For example, the EM results on Slc5a3 knockout mice do 
not resemble the synaptojanin 1 knockout mice with a defect in clathrin-
containing endosomal trapping and a similar lethal problem with 
hypoventilation[97].  
 Therefore, disturbances in the peripheral execution of breathing were excluded as 
the defect underlying the inability to breathe, and we rather suggest that the 
postnatal death of Slc5a3 knockout mice is due to a malfunction in their central 
respiratory center. 
Sections of brain including brainstem were processed for ultrastructural 
analysis by electron microscopy (EM).  The murine dissection and brain tissue 
preparation was performed when the experimental animals are sacrificed in the 
Animal Facility of Thomas Jefferson University.   For (EM), E18.5 fetuses were 
perfused transcardially using 3.8% acrolein and 2% paraformaldehyde in PB 
buffer (0.1 M phosphate buffer pH 7.4).  Thirty-micron thick sections were then 
cut through the entire brain of the fixed E18.5 embryos using a Vibratome and 
collected into 0.1 M PB. Sections were incubated in 2% osmium tetroxide in 0.1 
M PB for 1 h, washed in 0.1 M PB, dehydrated and embedded in Epon 812. 
Tissue sections selected for EM were taken from the region of the preBötzinger 
Complex.  Sectioning of tissues and EM imaging and analysis was performed by 
Dr. E. VanBockstaele at Thomas Jefferson University in Philadelphia.    Single 
thin sections of approximately 50–100 nm in thickness were cut using a diamond 
knife and stained with uranyl acetate followed by Reynold’s lead citrate. Sections 
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were examined with a Philips electron microscope.  Structures were defined as 
being proximal dendrites if they contained endoplasmic reticulum and were larger 
than 0.7 nm in diameter. Axon terminals were distinguished from unmyelinated 
axons based on their content of synaptic vesicles and diameter greater than 0.1 
nm.  No ultrastructural abnormalities were detected in cells of the preBötzinger 
Complex region in ventrolateral medulla of Ins-untreated mutant E18.5 fetuses. 
 
 
 
 
       
   
 
 
 
 
 
Figure 33.  Ultra-structural analysis of synapses in the brainstem of knockout 
mice at embryonic day 18.5. A, B, An axon terminal (at) forms an asymmetric 
(excitatory-type) synaptic specialization with a dendrite (d) in the preBötC region 
in a knockout mouse at E18.5. Thin black arrows indicate synaptic vesicles within 
the axon terminal. The thick black arrow denotes the synaptic junction. m, 
mitochondria. Bar = 500 nm. 
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No ultrastructural abnormalities were detected in cells of the preBötC 
region in ventrolateral medulla of Ins-untreated mutant E18.5 fetuses.  In figure 
33, an axon terminal (at) from a knockout fetus is shown. This axon terminal 
forms an asymmetric (excitatory-type) synaptic specialization with a dendrite and 
contains a mitochondrion and synaptic vesicles. As with other neurons examined 
in ventrolateral medullary sections from knockout fetuses, no pathological 
abnormalities were detectable. 
3.13 Quantitative PCR of Slc5a3 and Mrps6 messages 
Fetuses were collected at embryological age 18.5, their brains were  
isolated,  and immediately placed in liquid nitrogen for subsequent RNA 
extraction.  Tails from were used for the genotyping of the embryos.  Total RNA 
was extracted after homogeneization with a Polytron in 4 M guanidium-
isothyocyanate.  RNA purity was determined photometrically and 1µg of total 
RNA was used for reverse transcription using the Maloney murine leukemia virus 
transcriptase in a final volume of 40 µL as described. 
All quantitative real-time PCR (Taqman) primers and probes were 
obtained from Applied Byosystems (Weterstadt, Germany)(table 3).  Mouse 
glyceraldehyde 3-phosphatedehydrogenase (Gapdh) used as the constitutively-
expressed‘‘housekeeping” gene to normalize the levels of expression of all target 
genes.  Primers and probes are listed in table 3.  All PCRs were performed using 
0.5 µL of cDNA per reaction, in triplicates, in a final reaction volume of 25 µL on 
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an ABI prism 7700 Sequence Detection System (Applied Biosystems, Germany) 
using a 2-step PCR protocol following denaturing of cDNA (10 mins at 95oC) 
with 35 cycles of 95oC for 15 s and 60oC for 1 min.  Universal master mix were 
obtained from Applied Biosystems which included all reagents including Taq-
polymerase.  Dilutions experiments were performed to ensure similar efficiency 
of the PCRs, and standard curves were calculated referring the threshold cycle 
(Ct, the PCR cycles at which a specific fluorescence becomes detectable) to the 
log of each cDNA dilution step.   
All amplification batches included no template control (NTC), and cDNA 
aliquoted from brains of E18.5 wildtype and knockout, 1% inositol-treated and 
untreated.  Data were analyzed using standard statistical software, p values < 0.05 
were regarded as significant.   
As shown in figure 35, no difference in expression level was detected between the 
mutants and wildtypes, whether treated or untreated with myo-inositol. All the 
genes of interest show a fold increase and/or decrease not significantly divergent 
from the unit basal level of expression of Gapdh.  
The cDNA synthesized from brains of wildtype E18.5 fetuses for the purpose of 
RT-PCR analysis was also used to amplify the entire open reading frame (ORF) 
of the Mrps6 gene. Primers were designed to amplify all three exons of the Mrps6 
including exon1 which is shared with the gene of Slc5a3 (figures 3 and 34). The 
sequenced amplicon was found to be identical to the Mrps6 cDNA (NM080456) 
in GenBank. 
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Figure 34 Alignment of the shared exon1 of human SLC5A3 and MRPS6 
genes.  Base pairs in red with the ATG start codon are part of the open reading 
frame of the MRPS6 gene.  
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Assay ID Forward Primer Seq. Reverse Primer Seq. Reporter  Sequence 
    mSlc5a3 TGGCTGCTCCAATATTGCTTACC    GAAGGCCCACAGGAACCAA (FAM)-CACGCCTGGTGATGAC 
mSmit2 GGCTCTGTGGGATGGAAAAGAA CCTCCAAGGAAACTATGACAGGT (FAM)-CAAAGAGGAGCCCCCAAGCA 
mHmit ACCGGCTGTGCACCTG CACGCGGATGTACTCGATGTA (FAM)-CACCGCGGACTCGGA 
mIMPase1 GGAGGAGCAGATGCCTATTATGAA CCTGCCTCGGTGACAATGAT (FAM)-CAGCTCCCGCCATGTC 
mMIP CCAGGCCCAGGCATCAAG GGTGTGGGCTCTTTCTTGCA (FAM)-CACCAGCCCACTGCCT 
mMrps6 Proprietary (Applied Biosystem) Proprietary (Applied Biosystems) (FAM)-GCCGAGGAGGGTATTTCCTGGTGGA 
 
 
 
 
Table 3.  Primers and probes for qPCR of Slc5a3, Simt2, PtdIns synthetase, 
Mprs6, MIP, and IMPase1 genes.   
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Figure 35.  Level of expression of Slc5a3, Smit2, PtdIns synthetase, MIP and 
Impase1 genes in brain of Slc5a3 knockout, wildtype fetuses (WT, KO), myo-
inositol-treated and –untreated (WT+, KO+).  
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3.14 Immunostaining of the  pre-Botzinger complex 
The Pre-Botzinger (pre-BotC) complex constists of a cluster of neurons 
known to be involved in respiratory rhythmogenesis located in the ventrolateral 
medulla [95].  An immunohistochemichemical technique was developed to 
exactly localize and visualize these pacemaker neurons by targeting the 
neurokinin-1 receptors (NK1R) thought to be uniquely expressed in a neurons 
within the preBotC that are thought to be directly involved in the modulation of 
the inspiratory rhythm[98-102].   
Slc5a3 mutant carrier mice were bred, and the timing of pregnancies was 
determined from the appearance of vaginal plugs.  E 0.5 was considered the day 
of vaginal plug detection.   Fetal mice were delivered by caesarian section at day 
E18.5 from timed pregnant mice anesthetized with halothane (1.25–1.5% 
delivered in 95% O2 and 5% CO2) and maintained at 37°C by radiant heat. 
Newborn mice were anesthetized by inhalation of metofane (2–3%). 
Fixed medullary slices were processed containing (neurokinin 1 receptor) 
NK1R, and choline acetyltransferase (ChAT)-immunoreactive neurons within the 
ventrolateral medulla were examined following sectioning of the area of brains of 
E18.5 wildtype and knockout fetuses (figure 36). The rabbit polyclonal antibody 
to rat NK1R was previously characterized[103, 104].  Multiple transverse and 
sagittal sections (50µm) were collected and immunoreacted. Single- and double-
labeling experiments for NK1R (Advanced Targeting Systems, San Diego, CA), 
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and ChAT (Chemicon, Temecula, CA), were performed on free-floating sections 
according to the following protocol. Sections were rinsed in PBS and incubated 
with 1.0% bovine serum albumin (BSA; Sigma, St. Louis, MO) and 0.3% Triton 
X-100 in PBS for 60 min to reduce nonspecific staining and to increase antibody 
penetration. Sections were incubated overnight with primary antibodies (rabbit 
polyclonal anti-NK1R and anti-SST, diluted 1:1000; goat polyclonal anti-ChAT, 
diluted 1:400) diluted in PBS containing 0.1% BSA and 0.3% Triton X-100. After 
several washes in PBS, sections were incubated with secondary antibodies 
conjugated to the fluorescent probes Cy3-conjugated donkey anti-rabbit (Cy3-
DAR, 1:200; Jackson ImmunoResearch, West Groove, PA) and Cy5-conjugated 
donkey anti-goat (Cy5-DAG, 1:200; Jackson ImmunoResearch) diluted in PBS 
and 0.1% BSA for 2 hr. Sections were further washed in PBS and mounted and 
coverslipped with Fluorsave mounting medium (Calbiochem, San Diego, CA).  
3.14.1 Confocal imaging of the ventrolateral medulla preparations 
Mounted sections of brainstems were examined with a Zeiss (Oberkochen, 
Germany) 100M microscope (20X or 40Xobjective) using a LSM 510 NLO laser 
(Zeiss) and LSM 510 software (Zeiss). For Cy2 fluorescence, excitation was set to 
488 nm, and emissions were collected with a 505 nm long-pass filter. Acquired 
images were exported in JPEG format, and brightness and contrast were adjusted 
in Adobe Photoshop 7.0 (Adobe Systems, Mountain View, CA). 
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Figure 36.  Parasagittal sections of brainstem from wildtype and knockout 
E18.5 fetuses immunoreacted for neurokinin1 receptor (NK1R, red) and choline 
acetyltransferase (ChAT, green). NAc, nucleus ambiguus, compact formation; 
NAsc, nucleus ambiguus semicompact formation, preBötC, preBötzinger 
complex. Co-localization of both ChAT and NKR1 is indicated by the 
overlapping yellow staining.  
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3.15      Pathological examination of motoneurons of  Slc5a3 knockout mice 
E18.5 knockout fetuses do not exhibit gross abnormalities, and do not present 
any structural aberrations in brain, spinal cord or dorsal root ganglions [25]. Lung 
tissue was examined in E18.5 knockout fetuses without any evident pathology. In 
light of diaphragms electromyography findings, and of ventromedullary rhythmic 
activity electrophysiological recordings in preparations from Slc5a3 homozygous 
mutants, we examined the intactness of peripheral nerves including the phrenic 
nerve in the E18.5 knockout fetuses employing routine hematoxylin and eosin 
stains, and immunohistochemical staining of the neurofilament  proteins 
neurofilament medium (NF-M, 145-160kDa), and neurofilament heavy (NF-H, 
200-220kDa) found specifically in neurons, and no structural abnormalities were 
found.   
To investigate potential moto-neuronal impairments in E18.5 Slc5a3 
knockout fetuses,  transverse sections of the thorax containing the thymus and 
phrenic nerves of E18.5 knockout fetuses,  and sciatic nerve preparations from 
adult knockout mice were immunostained using a monoclonal antibody against 
the Thy 1.1 antigen, a 25–37 kDa heavily N-glycosylated, 
glycophosphatidylinositol (GPI) anchored cell surface protein, also a marker for 
the axonal processes of mature neurons (Figure 39).  
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3.15.1 Assessment of neuromotor function of Slc5a3 knockout mice from 
pathology slide preparations 
Figure 35 shows the hematoxylin and eosin staining of phrenic nerves in 
wildtype and knockout fetuses.  Figure 36 shows immunostaining of 
neurofilaments NF-M and NF-H in  phrenic nerve from myo-inositol-treated and -
untreated knockout and wildtype E18.5 fetuses.  Figure 37 shows abundant 
immunostaining in the thymus for Thy 1.1 antigen, but it is present in only half of 
the E18.5 wildtype fetuses. Unfortunately, detection the Thy 1.1 antigen in any 
peripheral nerve was not uniform in wildtype E18.5 fetuses and only a fraction 
displayed positive immunostaining.  Comparable findings were found in the 
knockout fetuses. Exposure of either group to myo-inositol did not affect the 
staining patterns. There are no significant or consistent histologic differences 
between E18.5 fetuses with or without maternal myo-inositol treatment. The 
phrenic nerves are present bilaterally, and of similar caliber, in E18.5 fetuses 
whose mothers were either treated or untreated with myo-inositol (Figures 37, 38 
and 39).   
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Figure 37. Hematoxylin and eosin stain of phrenic nerves of E18.5 wildtype 
(A,B, and C), and knockout (D,E and F)  fetuses.  
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Figure 38.  Monoclonal anti-neurofilament antibody against NF-M and NF-H, 
used to label phrenic nerve (indicated by the arrows) in myo-inositol-treated and –
untreated Slc5a3 knockout and wildtype fetuses. Magnification is 200X. 
 
 
 
 
              Wildtype                                Knockout 
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Figure 39.  Anti-Thy1.1 immunohistochemistry in E18.5 knockout fetus and 
adult knockout sciatic nerve. (A) Transverse section of fetal thorax: original 
magnification is 40X. T, trachea; E, esophagus; *, carotid artery, arrows-phrenic 
nerves. (B) Adult sciatic nerve: original magnification is 200X. 
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3.20 Statistical analysis  
 
 
Data listed on table 1 and 2 are expressed as mean ± standard deviation. 
Group differences in metabolite concentrations were tested by means of a one-
tailed t test using the program SigmaPlot (SYSTAT, Chicago, IL). P-values less 
than 0.05 were considered significant.   For real-time RT-PCR, assays were 
carried out in quadruplicate, and mean cycle threshold (Ct) values (± Stdev) were 
compared by two-way ANOVA (p ≤ 0.05 was considered significant).  
 
3.21.1 Calculations  
 
Percent reductions of myo-inositol of PtdIns in the samples were 
calculated in the following manner:  
100 ∗ [𝐻] − [𝐿][𝐻]  
Whereas percent increases were calculated  by the formula:  100 ∗ [𝐻] − [𝐿][𝐿]  
Where [H] and [L] indicate, respectively, the highest  (i.e., wildtype), or lowest 
(i.e, knockout) concentration of Ins, or PtdIns of the samples  
Fold changes in level of gene expression by qPCR (figure 34) were calculated 
from Ct value of each amplied plot in the PCR reaction.  The Ct is the cycle 
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number where exponential product formation is detected. Fold changes were 
calculated in the following manner: 
1. ΔCt = 𝑎𝑣Ct (target gene) - (control gene) 𝑎𝑣Ct 
2.  The ΔΔCt = ΔCt (wildtype) - ΔCt (knockout) 
3. The Fold change was then calculated:  2-[avΔΔCt] 
 
In MALDI-TOF MS analysis of PtdIns, the signal to noise ratio for each peak 
analysis was calculated using the equation: 
S/N = (I - (Nmax + Nmin)/2)/(Nmax -Nmin)  
Where I is the maximum intensity of a peak, and Nmax and Nmin are the maximum 
and minimum of the background noise. 
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CHAPTER 4   SUMMARY, CONCLUSION AND FUTURE WORK 
4.1  Summary 
Myo-inositol is one of most ubiquitous organic elements in living 
organisms, widely distributed in animals, plants and microorganisms in free and 
phoshorylated forms, and in inositolphospholids.  In mammals two important 
physiological roles of have been assigned to this multi-funtional polyol: it’s an 
important osmolyte, and essential in the phosphoinositide signal transduction 
pathways.  These two important roles of myo-inositol have been well documented 
throughout the last fifty years, and while there is a plethora of scientific literature 
on these two functions, none of them captures the significance of the variations in 
tissue myo-inositol concentrations in mammals, its requirement in central nervous 
system where it is particularly abundant, and most of all in the developing fetus.  
Myo-inositol is also present in high millimolar concentrations  in cortical and 
cerebellar regions of the brain which supports the idea that  metabolism of this 
carbohydrate-like compund is  related to brain function,  hence perturbations of 
this polyol have been of particular  interest to the molecular psychiatrist studying 
bipolar disorders, Alzheimer’ disease, or Down syndrome’s  behavioral 
phenotype.  Among many unanswered questions about myo-inositol’s 
physiological role in mammalian cells is one which addresses the importance of 
exogenous dietary myo-inositol acquired by cells by active transport via the 
SLC5A3 Na+/myo-inositol symporter, versus the endogenous de novo synthesis of 
the polyol from glucose-6-P, and whether one mechanism alone would be 
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sufficient to ensure homeostasis of intracellular Ins and normal cellular functions 
and cell survival.     
To investigate the role of myo-inositol in vivo and potential deleterious 
effect of depletion of intracellular myo-inositol, hence its physiological and 
biochemical functions, I took part in the development of a murine knockout 
model to effectively study consequential physiological, and biochemical activities 
in cells in which the activity of the major mammalian Na+/myo-inositol 
cotransporter is completely obliterated.  Interestingly, the SLC5A3 gene is 
embedded within exon 2 of the mitochondrial 28S ribosomal protein S6 gene.  
The two genes share the same telomeric region on the human chromosome 21, 
and are aligned along the same transcriptional orientation.  Data from genomic 
sequence analysis show that both genes share exon1, which is part of the reading 
frame of the MRSP6 gene, but not of the SLC5A3.  Studies show that the Mrps6 
RNA message exists as a spliced form in which exon 2 of the Slc5a3 gene located 
within the intron 1 of the Mrps6 is excised from the approximately 70 kb gene 
transcript. Indeed, exposing melanoma cells under isotonic and hypertonic 
conditions shows that only one mRNA contains the entire reading frame of 
SLC5A3 [105], and polymerase chain reaction analysis  of a cDNA library from 
brains of E18.5 fetuses using Mprs6-specific yields an amplicon containing all 
three exons of the Mrps6 spliced message.     
Similarly to the Slc5a3 gene, the Mrps6 gene is highly expressed in brain 
of the trisomy 16-like Down syndrome murine model in which both genes appear 
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to manifest the predicted gene dosage effect[23], and in brain tissues from 
subjects with Parkinson’ disease[106].  To investigate whether this unique 
topology of the two cognate genes has any functional significance, or share a 
common osmoregulatory control mechanism by the presence of a co-regulatory 
motif within their promoter region, I performed quantitative PCR but did not 
observe differential gene expression of Mrps6 in Slca53 knockouts proving that 
the Mrps6 gene was not disrupted following ablation of the Slc5a3 open reading 
frame.  However, the Mrps6 gene may still deregulated in the early stages of 
development since the study examined the E18.5 fetuses, and therefore I cannot 
discount the role of the Mrps6 in the lethality of our animal model.   
The Slc5a3 gene knockout is a unique animal model that enabled us to 
study for the first time the biochemical implications of a drastic reduction of myo-
inositol in the developing Slc5a3-null mouse embryo, as well as in adult mice.  
The disruption of the Slc5a3 gene does not produce a clear morphological 
phenotype, but knockout newborns die right after birth, about twenty minutes 
post-partum, develop normally and their weights at birth are comparable to those 
of their wildtype counterparts, and have no gross physiological malformations.   
Although a physiological phenotype has not been proposed for the Slc5a3 
knockout model, we hypothesize that the Slc5a3 knockout newborns die 
postpartum due to hypoventilation based on electrophysiological studies done by 
one of  us, Dr. John Greer, a collaborator in this project at the University of 
Alberta in Canada, in which diaphragm electromyography recordings from Slc5a3 
knockout at embryonic age 18.5 show irregular respiratory rhythmic patterns, 
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indicating that a severe reduction in brain of  myo-inositol  may be detrimental at 
the moto-neuronal level in which transmission of the respiratory path from the 
preBötzinger complex, the brainstem respiratory pacemaker, to the diaphragm via 
the phrenic nerves is severely impaired.  Histological examinations of E18.5 
knockout fetuses using an immunomarker antibody against the PtdIns-anchored 
ectoprotein thy 1.1 show that peripheral nerve structure is normal, also confirmed 
by electrophysiological recordings which demonstrate that the phrenic nerve 
structure is conserved and functional.   
The Slc5a3 knockout phenotype can be” rescued” by supplementing the 
drinking water of the pregnant dam with 1% myo-inositol.  This treatment ensures 
survival of Slc5a3-null mice, but it is only effective if administered until weaning 
at 21days post-partum.  Interruption of the 1% myo-inositol treatment in perinatal 
phase results in a premature death of the newborn Slc5a3 knockout mice.   
Mesurements of myo-inositol in brains of E18.5 knockout mice in the second 
study revealed a drastic 96% in the basal level of the polyol, and 90% reduction in 
whole body and 88% in torso.   Following myo-inositol treatment, basal levels of 
myo-inositol in knockout E18.5 fetuses were still drastically depressed, but show 
a twofold increase in comparison to the untreated E18.5 knockout fetuses.  This 
50% increase may at first appear to be of vital importance to the developing 
mouse as the myo-inositol treatment is indispensable for the survival of the 
newborn Slc5a3 homozygous mutants, but this increase per se may not be of 
physiological importance.  To better assess the impact of ectopic myo-inositol in 
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the rescue of the phenotype, myo-inositol and PtdIns concentration levels were 
ascertained in whole embryos collected at the earlier stage of development of 
E10.5,  a stage in which more profound morphogenetic changes occur.   At this 
early stage of mouse development basal levels of myo-inositol are in the order of 
0.3 nmoles/mg of tissue, while in Slc5a3 homozygous mutant E10.5 embryos 
levels of the metabolite are drastically reduced by 69.7% to 0.1 nmoles/mg of 
tissue.  In treated E10.5 embryos myo-inositol levels are normalized.  To date, the 
most poignant scientific data collected from the study of this mouse model, in an 
effort to evaluate a biochemical cause of death in the newborn homozygous 
mutant, come from the phosphatidylinositol measurements in E10.5 Slc5a3 
knockout embryos.  In these mutants, the levels of phosphatidylinositol are 
reduced by a 50%, while in treated E10.5 knockout this inositol phopholipid is 
completely restored to basal wildtype level.  This finding may outline for the first 
time a biochemical phenotype in which depletion of myo-inositol hinders the 
synthesis of PtdIns, thus disrupting important signaling events including calcium 
transits and akt/PKB pathway, and  limited binding of structural proteins to 
polyphosphoinositides due to the scarcity of these inositol lipids, resulting in an 
aberration of intracellular vesicle trafficking.  This latter point is supported by 
studies done on the synaptojanin-1 knockout model which shows similarities to 
the Slc5a3 knockout model and a  deficiency of phosphatidylinositol-4,5-P2-5'-
phosphatase isoform in clathrin-coated vesicles of nerve terminals[97].  This 
genetic model similarly to the Slc5a3 knockout model shows that a potentially 
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lethal perturbation in neurotransmission related to synaptic vesicle protein 
recycling in post-uterine life, but does not effect embryonic development. 
The Slc5a3 knockout model may be a prototype in which phosphoinositide 
deficiency leads to neuronal signaling aberrations along the neuroaxis, and most 
notably having an injurious impact on the respiratory control center within the 
pre-Bötzinger complex, as evidenced by electrophysiological analysis of E 18.5 
fetuses which show abnormal respiratory rhythmogenesis at a time when 
breathing becomes continuous and independent.  In the mammalian fetus 
breathing is episodic, but becomes continuous after birth. Since in fetal state 
breathing is partially inhibited by a partial hypoxic environment, it is possible that 
following birth the activity of the neuronal cluster within the pre-Bötzinger 
complex is impaired by imprinted subcellular developmental lesion, or defects 
induced because of abnormal signaling events related to PtdIns deficiency in the 
early stages of embryonic development.   
4.2  Conclusion 
 The main aim of my thesis work was to test the “inositol deletion 
hypothesis” first proposed by Berridge[81] which postulates that intracellular 
myo-inositol depletion results in the reduction of levels of phosphatidylinositol, 
phosphatidylinositol-4-P and phoshatidylinositol-4,5-P2 .  Although the theory has 
never been substantiated by direct measurements of the phosphoinositides 
including phosphatidylinositol, its contenders base their claim purely on works 
done on lithium in an effort to suggest a metabolic explanation for its therapeutic 
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use in the treatment of bipolar disorders.  Lithium exerts its effect on inositol-
phosphate signaling,  and it is an inhibitor of inositol monophosphatase [82] and 
polyphosphatase [83], two enzymes involved in the breakdown and recycling of 
inositol-1,4,5-P3.  It is more likely that the accumulation of inositol-1-P and or 
related inositol phosphates, and /or the effects of lithium on inhibition of GSK-3 
and other proteins resulted in the alterations in neuronal metabolism.   
In an attempt to delineate a behavioral phenotype of myo-inositol 
depletion comparable to that of lithium treated mice, Shaldubina et al., in a 
publication we co-authored,  studied the behavior of Slc5A3 heterozygous mutant 
adult mice.  In these mice free myo-inositol levels are reduced by 15% in the 
frontal cortex and by 25% in the hippocampus, and they do not differ from the 
wild-type counterparts in various behavioral tests such as cholinergic-mediated 
lithium–pilocarpine seizures, apomorphine-induced stereotypic climbing model of 
dopaminergic system function, in the Porsolt forced-swimming test model of 
depression, and in the elevated plus-maze model of anxiety.  Although reduction 
in brain myo-inositol levels in the heterozyogous mice are comparable to that of 
brain myo-inositol of mice exposed to chronic lithium treatment, which is in the 
same range of 10 to 25%, the Slc5a3 mutant carriers lack a comparable behavioral 
phenotype.  
The murine Slc5a3 knockout model is the first animal model in which 
myo-inositol levels are markedly reduced and ever observed in any other living 
system, either in lower or complex organisms, hence, it allowed us to evaluate the 
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long held “inositol depletion hypothesis” by directly testing whether intracellular 
myo-inositol insufficiency leads to a dampening of phosphatidylinositol synthesis 
by direct measurements of these membrane phospholipids utilizing the most 
innovative instrumentation available today.   Although a quasi-total depletion of 
intracellular myo-inositol in brains of Slc5a3-null E18.5 fetuses failed to 
demonstrate disruption of membrane phosphatidylinositol, in Slc5a3-knockout 
embryos at fetal stage 10.5 myo-inositol reduction led to a 50% decrease in 
membrane-bound PtdIns.  Therefore, ablation of the major murine Na+/myo-
inositol symporter gene generates a metabolic phenotype that allows us to further 
investigate the mechanism of lethal inositol deficiency, and to re-evaluate the 
“inositol depletion hypothesis”.   Indeed, the most compelling  scientific evidence 
outlined in this thesis is that  severe myo-inositol deficiency in the murine   Slc5a3 
knockout species leads to a deficiency of phosphatidylinositol levels in the 
earliest stage of embryogenesis in which de novo synthesis of the polyol is not 
sufficient  to maintain cellular myo-inositol levels, and below the required 
substrate level to maintain adequate phosphatidylinositol synthetase activity, and 
thus not adequate for the synthesis of PtdIns,  prior to full neuronal development 
and axonal arborization, and that rescue of the phenotype alleviates the lethal 
effect of inositol deficiency by increasing the myo-inositol threshold during which 
time phosphatidylinositol levels are restored to a viable and life sustaining level.  
My work suggests that myo-inositol levels must be maintained somewhere 
between 100 and 300 nmol/L in the murine embryo to prevent a lethal deficiency 
of signalling phosphoinositides.  Interestingly, this range is not dissimilar from 
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the basal levels of myo-inositol within the blowfly salivary gland cells used 
originally by Berridge to generate the ‘inositol depletion hypothesis’, yet 
markedly different from he basal levels detectable in fetak and adult mammalian 
brain.  
4.3 Recommended Future Work 
The work I am presenting in this thesis is an attempt to elucidate a 
biochemical and, or a physiological phenotype of a mouse model that lacks the 
major membrane myo-inositol transporter.  Moreover, the experiments I outlined 
were designed with the intent of investigating a pattern of aberration at the 
neuronal level, in term of nerve transmission from the respiratory pacemaker from 
the ventromedullary region to the diaphragm though the phrenic nerves, and at the 
biochemical level by specifically measuring levels of PtdIns in this model where 
myo-inositol is depressed of as much as 96% in the preterm fetuses.  PtdIns levels 
were found to be comparable to those in wildtype mice, except in the early stagy 
of embryonic development where myo-inositol levels are diminished by a 69.7 %, 
but result in a 47% reduction of the PtdIns pool.  PtdIns measurement in the 
knockout model was driven by the logical approach dictated by what we know 
about PtdIns and myo-inositol metabolism, by what has been suggested by the 
literature on the subject of PtdIns synthesis, and most of all by the convincing 
‘inositol depletion hypothesis’.  In my opinion future work should be directed 
toward measurements of PtdIns-4,5-P2 in embryos and fetuses Slc5a3 knockout 
mice.  The dogmatic assumption that PtdIns-4,5-P2 levels are normal there where 
PtdIns levels do not change may not be correct.  PtdIns is synthesized in the 
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endoplasmic reticulum and reaches the cellular membrane either by vesicular 
transport, or by transport proteins.  It’s is possible that this pathway is aberrant, 
and that only a fraction of PtdIns reaches the membrane, therefore limiting the 
synthesis of PtdIns-4,5-P2 which occurs exclusively at the membrane level.  
Measurements of polyphosphoinositides  has proven to be an arduous task due to 
the limited size of the early embryos, and to ion suppression effects during 
MALDI-TOF MS lipidomic analyses, but detection  and quantification of these 
liable lipids could perhaps be improved by a more sensitive analytical 
instrumentation.  
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